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Abstract: Background 
Rare cancers here defined as those with an annual incidence rate less 
than 6/100,000 in Europe, 
 pose challenges for diagnosis, treatments, and clinical decision-making. 
Information on rare cancers is scant. We updated the estimates of the 
burden of rare cancers in Europe, their time trends in incidence and 
survival, and provide information on centralization of treatments in 
seven European countries. 
Methods 
We analysed data on more than two million rare cancer diagnoses, provided 
by 83 cancer registries, to estimate European incidence and survival in 
2000-2007 and the corresponding time trends during 1995-2007.  Incidence 
rates were calculated as the number of new cases divided by the 
corresponding total person years in the population. Five-year relative 
survival (RS) was calculated by the Ederer-2 method. Seven registries 
(Belgium, Bulgaria, Finland, Ireland, Netherlands, Slovenia, and the 
Navarra region in Spain) provided additional data on hospitals of 
treatment for about 220,000 cases diagnosed in 2000-2007. Hospital volume 
was calculated as the number of treatments provided by each hospital rare 
cancer group sharing the same referral pattern.  
Findings 
Rare cancers accounted for 24% of all cancers diagnosed in EU28 during 
2000-2007. The overall incidence rose yearly by 2.3%. RS  increased 
(overall 5.7%), from 1999-2001 to 2007-2009, and for the majority of rare 
cancers, with the largest increases for hematological tumors and 
sarcomas. The level of centralization of rare cancer treatment varied 
widely between cancers and between countries. The Netherlands and 
Slovenia had the highest treatment volumes. 
Interpretation 
The study profits from the largest pool of population-based registries to 
estimate incidence and survival of about 200 rare cancers. Incidence 
trends can be explained by changes in known risk factors, improved 
diagnosis, and registration problems. Survival could be improved by early 
diagnosis, new treatments and better case management. There is ample room 
for improving the centralization of treatment in these seven European 
countries. 
The research was funded by the European Commission (Chafea) [Grant No. 
2000111201]. 
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Summary  
Background 
Rare cancers here defined as those with an annual incidence rate less than 6/100,000 in Europe, 
 pose challenges for diagnosis, treatments, and clinical decision-making. Information on rare 
cancers is scant. We updated the estimates of the burden of rare cancers in Europe, their time 
trends in incidence and survival, and provide information on centralization of treatments in seven 
European countries. 
Methods 
We analysed data on more than two million rare cancer diagnoses, provided by 83 cancer 
registries, to estimate European incidence and survival in 2000-2007 and the corresponding time 
trends during 1995-2007.  Incidence rates were calculated as the number of new cases divided 
by the corresponding total person years in the population. Five-year relative survival (RS) was 
calculated by the Ederer-2 method. Seven registries (Belgium, Bulgaria, Finland, Ireland, 
Netherlands, Slovenia, and the Navarra region in Spain) provided additional data on hospitals of 
treatment for about 220,000 cases diagnosed in 2000-2007. Hospital volume was calculated as 
the number of treatments provided by each hospital rare cancer group sharing the same referral 
pattern.  
Findings 
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Rare cancers accounted for 24% of all cancers diagnosed in EU28 during 2000-2007. The overall 
incidence rose yearly by 2.3%. RS  increased (overall 5.7%), from 1999-2001 to 2007-2009, and 
for the majority of rare cancers, with the largest increases for hematological tumors and 
sarcomas. The level of centralization of rare cancer treatment varied widely between cancers and 
between countries. The Netherlands and Slovenia had the highest treatment volumes. 
Interpretation 
The study profits from the largest pool of population-based registries to estimate incidence and 
survival of about 200 rare cancers. Incidence trends can be explained by changes in known risk 
factors, improved diagnosis, and registration problems. Survival could be improved by early 
diagnosis, new treatments and better case management. There is ample room for improving the 
centralization of treatment in these seven European countries. 
The research was funded by the European Commission (Chafea) [Grant No. 2000111201]. 
 
Introduction 
The RARECARE project defined rare cancers as those with an annual incidence rate less than 
6/100,000 in Europe (EU), and showed that about one in five were rare types and slightly more 
than four million rare cancers were prevalent in the EU population [1]. Because of their low 
numbers, the almost 200 rare cancers listed by RARECARE pose challenges for diagnosis, 
treatments, and clinical decision-making. Clinical trials are rare too, and it is hard to build up new 
knowledge and expertise.  
There is a broad consensus that the diagnostic pathologic confirmation and primary treatment of 
rare cancers, in particular, should be centralized in reference centers and/or in collaborative 
networks, with multidisciplinary approaches [2] and very specific expertise. In addition, clinical 
and translational research calls for a high level of centralization and international collaboration. To 
what extent appropriate policies for rare cancer patients are implemented at the country level has 
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seldom been studied.  As a consequence, information for policy makers and stakeholders is 
scarce for many of these tumors. 
The project Information Network on Rare Cancers (RARECAREnet) is designed to update 
epidemiological information on rare cancers in the EU [3], to provide indicators at the country 
level, time trends, and to study to what extent treatment is centralized in Europe.  
This paper provides up-to-date incidence and survival estimates based on data collected from 94 
population-based cancer registries (CRs), for 198 rare cancers diagnosed in 2000-2007 and for 
12 major families of rare cancers. It also presents data on the levels of centralization for rare 
cancers in selected European countries.  
Material and Methods 
Patients 
The data were extracted from two databases. The first, the descriptive analysis database, is a 
subset of the EUROCARE-5 database [4]. It includes incidence and follow-up data provided by 
European population-based CRs regarding cancer patients diagnosed in the period Jan 1,1978 to 
Dec 31, 2007. Vital status was updated to Dec 31,  2008. From the 117 CRs participating in 
EUROCARE-5, we excluded specialized pediatric CRs, the Swedish and Turin CRs, because 
they did not participate in the RARECAREnet study, and the Danish CR, because it provided 
none of the details on morphology needed to define rare cancers. Details of the RARECAREnet 
database can be found in the report on the project website [5]. For the analysis of incidence we 
excluded 11 CRs specialized in specific anatomical sites to avoid incomplete coverage of some 
cancer entities affecting multiple sites such as neuroendocrine tumors. A total of 1,984,147 rare 
cancer diagnoses were considered for incidence estimates in 2000-2007, collected by 83 CRs 
from 1,566 million person-years of observation. Data for incidence trends came from 42 CRs 
covering the period 1995-2007, and included 2,268,602 cases, and 1,900 million person-years of 
observation. Survival estimates in 2000-2007 for all the rare cancers were based on a total of 
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1,994,346 diagnoses, observed by 94 CRs. Case identified only with death certificate (DCO) or 
casually discovered at autopsy were excluded from the analysis because they do not report time 
of survival. Cases lost to follow-up were considered as censored at the date of last contact.  
Multiple primaries in a same patient were included. Death certificate only (DCO) and autopsy 
cases were excluded but data included multiple primaries in a single patient. Finally, survival 
trend analysis was based on 1,649,309 rare cancer diagnoses from 45 CRs providing 
uninterrupted data from at least Jan 1, 1995 to Dec 31, 2007.  
The second database was used for the study of hospitals of treatment and hospital volume. It 
comes from seven European CRs: the national CRs of Belgium, Bulgaria, Finland, Ireland, 
Netherlands, Slovenia, and the regional CR of Navarra (Spain). This last, although regional, was 
added in consideration of the regional organization of the Spanish health care system. These 
CRs were selected to reflect the variability of incidence and survival in Europe [1,5], and because 
they could provide detailed data for all 198 rare cancers. Variables included: sex, dates of birth 
and diagnosis, topography and morphology codes, from the International Classification of 
Disease for Oncology version 3 (ICDO-3) grading, pathological and clinical TNM, simplified stage 
(localized, regional extension, metastatic), treatment (surgery, radiotherapy, systemic, other or 
none), vital status, date of closure of follow-up or death, hospital of diagnosis and hospital of 
treatment.  DCO and autopsy cases (1.3% overall, with a maximum of 8.6% in Bulgaria) were not 
included. The hospital of diagnosis was defined as the hospital where the pathology examination 
was done or requested. The hospital of treatment(s) was defined as the hospital where a specific 
treatment (e.g. surgery) or the first course of systemic therapy (e.g. chemotherapy) was given. Up 
to five different types of treatment within one year from the date of diagnosis were considered as 
a primary treatment. Vital status was further updated, with respect to the descriptive analysis 
database, to Dec 31, 2012. 
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We received data on about 348,000 rare cancers diagnosed in the period 2000-2007. However, 
national data from Belgium were limited to the period of diagnosis 2004-2007, and those from 
Navarra to 2000-2005. Cases diagnosed in Bulgaria and the Netherlands during 2000-2004 were 
removed on account of incomplete national coverage of hospital information. A total of 223,081 
rare cancer cases were included in the hospital volume study database. Unspecific morphologies 
(8000, 8001, 8010, 8800, 9800, 9590) were found in 2.1% of cases, with the highest proportion 
(4.1%) in Finland. Seventeen per cent of cases (37,959/223,081) was removed, because for them 
the information of hospital was missing. 
Methods 
Rationale of the definition of rare cancer entities and their classification in terms of ICD-O codes 
are reported elsewhere [1,2,5]. Classification was structured in way to avoid any overlapping 
among rare entities. For example, GEP NET and GIST tumours were under the families of NET 
and sarcomas, and not also in digestive rare cancers. 
Incidence rates were estimated as the number of new cases arising in 2000-2007 divided by the 
corresponding total person years (male + female) in the general population. The European 
standard population was used for direct age standardization. New cases in 2013 in EU28 were 
calculated by multiplying age- and sex-specific incidence rates in 2000-2007 by the 
corresponding European population classified in five-year age classes on 1 January 2013. 
Incidence variation over time was estimated restricting the analysis to 1,480,424 cases diagnosed 
in the two sub-periods 1999-2002 and 2003-07, and was presented in a funnel plot where each 
dot represents a single rare cancer, the y-axis displays the estimated difference in terms of 
annual percent change (APC) of age-adjusted incidence, and the x-axis the corresponding 
precision in terms of the inverse of its standard error. APC was calculated as the ratio between 
incidence rates for the two sub-periods elevated to 1/4.5, the inverse of their mean time distance. 
Three-standard-deviation confidence intervals for estimated zero changes [6] are represented by 
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two symmetrical lines progressively approaching the x-axis with increasing x values. Dots lying 
above or below the area between them correspond respectively to tumors with 99.8% significantly 
higher or lower incidence rates. 
Five-year relative survival (RS) was estimated as the ratio of observed to expected survival in the 
general population, matched by age, sex, calendar year, and geographical area, and calculated 
by the Ederer-2 method [7].  RS time trends were estimated by the period approach considering 
three follow-up periods: 1999-2001 (cohorts diagnosed in Jan 1,1995 to Dec 31, 2001), 2002-04 
(cohorts diagnosed in Jan 1,1998 to Dec 31, 2004), and 2005-07 (cohorts diagnosed in Jan 1, 
2001 to Dec 31, 2007). RS changes were presented as a funnel plot, similarly to incidence 
changes, but using the difference between five-year RS in the last and first of these periods on 
the y-axis. 
The volume (number) of treatments provided by each hospital was calculated for major cancer 
groups, defined by aggregating all the solid rare cancers into 38 groups sharing the same referral 
pattern (see Figure 3). For example, all the 17 head and neck tumors, identified [1] as clinically 
distinct rare entities, are usually referred to head and neck specialized services, and were 
considered as a single group. Hematological rare tumors, not always requiring hospitalization, 
were not considered in the volume analysis.  Hospital volume for each of the 38 groups was then 
computed as the annual number of any treatment delivered by the hospital, for all the cancers in 
that group. Repeated admissions to the same hospital for the same cancer and the same 
treatment type (i.e. surgery, radiotherapy or systemic therapy) were considered as a single 
admission and counted as one treatment in the analyses. Instead, repeated admissions for 
several treatment types (such as radiotherapy and subsequent surgery) given to a patient in the 
same hospital were all counted as treatments. Untreated patients were assigned to the hospital of 
diagnosis. The total number of treatments provided by each hospital for a given group of rare 
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cancers was then divided by the number of years of observation to provide its mean annual 
hospital volume.  
Finally, for each patient we calculated the mean annual volume of the hospital(s) where they were 
treated, so obtaining a patient-specific measure with a much less skewed distribution with respect 
to the hospital-specific volume. Averaging this measure over all the patients diagnosed with a 
given group of rare cancers in a certain country gives a cancer- and country-specific measure of 
the level of expertise that patients can expect for the treatment of their tumor. We called it the 
mean admission volume (MAV) indicator. 
Role of the funding source 
The funders had no role in study design, collection, analysis or interpretation of data, or writing of 
the report. The corresponding author had full access to all the data and had final responsibility for 
the decision to submit for publication. 
Results 
Burden of rare cancers in Europe 
Table 1 provides incidence and survival estimates for each of the 198 rare cancers, for 63 groups 
of rare cancers (capital letters), for the 12 wider families in which rare cancers are hierarchically 
grouped, and for six common cancer groups.  Hematological malignancies, rare cancers of 
female genital organs and of the digestive tract, and head and neck cancers were families with 
the highest overall incidence rates (from 15 to 28/100,000/year). Thoracic cancers, male genital 
and urological, endocrine organs, central nervous system (CNS) tumors and sarcomas had 
overall incidence rates from 5 to 8/100,000. Rare skin cancers and non-cutaneous melanoma, 
and embryonal cancers were the families with the lowest rates (1.22 and 0.34 per 100,000). 
Overall, rare cancers accounted for 24% of all cancers diagnosed in EU28 during 2000-2007; by 
far the majority were solid cancers (76%). For sex-specific rare cancers, we also provide in 
supplementary table (see appendix p 1) sex specific incidence rates. 
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Five-year RS of all rare cancers together was 49%, compared to 63% for all common cancers.  
Rare cancers also had lower survival within the families of digestive cancers (15% vs. 41%), 
female genital cancers (58% vs. 82%), male genital and urologic cancers (74% vs. 76%), skin 
cancers (70% vs. 96%) and hematological tumors (51% vs. 61%). The only exception was the 
group of thoracic cancers (13% vs. 10%), where common cancers included squamous cell 
carcinoma of the lung - with a very bad prognosis (6% after five years).  Families including only 
rare cancers had five-year RS ranging from high, as for embryonal and endocrine organ tumors 
(79% and 88%), to intermediate, for sarcomas (60%), neuroendocrine (54%) and head & neck 
tumors (52%), and low for CNS tumors (21%).  
Time trends of incidence and survival for rare cancers are shown in Figures 1 and 2. Cancers 
whose incidence variation fell outside the confidence interval shown in Figure 1 are listed in Table 
2, with the age-standardized incidence estimates for 1999-2002 and 2003-2007, the 
corresponding APC and three-standard-error confidence intervals. Rare cancer dots in the plot 
seem to be distributed fairly symmetrically around the zero-change line, indicating no major 
systematic shifts in incidence. Overall there was a slight increase: the average APC for all the 
entities was +2.3% per year.  There was a significant increase in incidence (99.8%) for 16 rare 
cancers, and a significant decrease for ten. Trends of rare cancers did not substantially differ 
from those of common cancers (data not shown), whose average annual change was +0.9%. 
Only prostate and skin cancers had an APC greater than 2%, while only epithelial cancers of the 
stomach decreased more than 2%.  
Survival increased from 1999-2001 to 2005-2007 for the majority of rare cancers. The cloud of 
points in Figure 2 is skewed upward from the zero line, corresponding to a mean increase in 
survival, averaged over all the entities, of about 5.7 percent points. Twenty-four rare cancers 
presented significant survival increases (Table 3), while only one (other myelodysplastic 
syndromes) had a slight but significant decrease. Rare cancers with the largest survival increases 
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were mainly hematological: chronic myeloid leukemia, diffuse B cell lymphoma, follicular 
lymphoma, precursor B/T lymphoblastic leukemia/lymphoma, and multiple myeloma. Well 
represented among the top tumors with increasing survival were sarcomas, specifically of the 
viscera, trunk, and Kaposi sarcoma. Survival increases higher than five percent points were also 
observed for infiltrating ductal carcinoma of the prostate (12 percent points), poorly differentiated 
endocrine carcinoma of the digestive system (7.5 percent points), and squamous cell carcinoma 
of the oropharynx (7.1 percent points). There were no major improvements for rare cancers of the 
colon, rectum, breast and kidney, differently from the corresponding groups of common cancers 
[8].  
 
Where are rare cancers treated?  
Figure 3 illustrates the extent of centralization of rare cancer treatment, presenting MAV, overall 
and by country, for 38 cancer groups ranked by decreasing incidence. Logarithmic scale is here 
used for the x-axis to made the graph readable despite the huge MAV variability (from 82 to 0.2 
per year) across the considered cancers.  A supplementary Table (see appendix p 3) gives the 
numbers for the graphs. Pooled MAV (Figure 3a) ranged from a maximum of 83 treatments per 
year for head and neck tumors to fewer than 0.5 per year for choriocarcinoma of the placenta, 
some embryonal and endocrine tumors. The higher the incidence, the larger the MAV of treating 
hospitals. The relationship between cancer incidence and MAV in the pool of countries was very 
strong (Pearson coefficient 0.88), though with several outliers. This was the case for epithelial 
tumors of the ovary, which had a higher incidence but a lower MAV than CNS tumors, whose 
patients seemed therefore to be more centralized than ovarian cancer patients (35 vs. 20 cases 
treated per year). Similarly, soft tissue sarcomas had a five times higher incidence, but received 
less centralized treatment than bone sarcomas. Treatment  for for thyroid cancers, uveal 
melanoma and several embryonal tumors appeared to be fairly concentrated in few hospitals with 
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relatively high volumes. In contrast, tumors of the urinary tract, gastro-entero-pancreatic 
neuroendocrine tumors (GEP-NET), small intestine, non-epithelial ovary cancers, and NET of 
skin were treated in centers with an even lower MAV than would be expected because of their 
very low occurrence.  
With some exceptions, country-specific patterns of MAV reflected the overall picture. Differently 
from what found in the other countries, the management of epithelial ovarian cancers was highly 
centralised In Bulgaria and Slovenia. CNS patients were treated in highly centralized structures in 
all countries except Finland and Navarra. Treatment for uveal melanoma and retinoblastoma was 
not centralized in Bulgaria and, again, in Navarra. Slovenia and the Netherlands had the highest 
centralization patterns, while MAV for the majority of cancers was very low in Navarra. 
Table 4 presents, for each country and 29 rare cancers, the annual number of cases diagnosed, 
the number of top-volume hospitals treating at least 75% of national cases, and the average 
annual numbers of treatments provided. Taking for example head and neck cancers, 3/4 of 
patients were centralized in two top hospitals in Slovenia (2 million population, 266 treatments per 
hospital per year), and 12 top hospitals in the Netherlands (17 million population, 201 treatments 
per hospital per year). The level of centralization was lower in the other countries, resulting in a 
caseload of 145 in the ten Bulgarian top hospitals, 106 in the 29 Belgian hospitals, and 
respectively 83, 77, and 63 in Finland, Navarra and Ireland. The Netherlands and Slovenia had 
the highest treatment volumes out of the 29 considered, with 12 rare cancers each. 
 
Discussion 
Rare cancers make up one quarter of all malignancies. They are a very heterogeneous group of 
almost 200 cancers, mostly solid, constituting from 2% of all skin cancers up to 32% of all female 
genital cancers. We confirmed the lower five-year survival for rare than common cancers (49% 
vs. 63%), and for all cancer families except  thoracic cancers. The disadvantage persisted even 
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after excluding common cancers with good prognosis, of prostate, breast and skin. Several 
factors help explain these differences: the biology of the diseases, adequacies of diagnosis and 
treatment, lack of effective therapies, or lack of evidence-based treatment guidelines. 
A novelty of this study is the analysis of incidence and survival trends. Overall, incidence rose by 
2.3% a year from 1999 up to 2007. The increase was substantial for several rare cancers (Figure 
1). Some of the increase can probably be attributed to improvement in pathological diagnosis,  
new entity codes in the ICD-O-3 and to the time needed to adapt the coding procedures. This is 
the case of GIST, large cell carcinoma of the lung, neuroendocrine tumours and many 
hematological codes [9-11]. For other rare cancers, increases in incidence may be due to better 
pathological diagnosis, like for the neuroendocrine tumors. For thyroid carcinoma several authors 
have suggested an increase in over-diagnosis [12]. However, increased exposure to risk factors 
may explain higher incidence rates for oropharynx and anal canal squamous cell cancers due to 
human papillomavirus (HPV) [13,14] and for adenocarcinoma of the esophagus, perhaps due to 
increasing obesity or gastro-esophageal reflux [15]. The lower squamous cell carcinoma cervix 
incidence might reflect organised cervical screening programs. The drop in incidence for some of 
the rare cancers was due to the still falling prevalence [16] of smoking . 
RS improved by about 3% overall, slightly less than for common cancers (5.5%, data not shown), 
suggesting that investments were more focused on these latter.  Also, over-diagnosis is expected 
to affect more common than rare cancers. Success was greatest for chronic myeloid leukemia 
(CML) with a five-year gain in survival of 21% across the study years, largely explained by the 
widespread use of new and more effective treatments, such as targeted treatments and more 
effective stem-cell transplantation [17]. For many other hematological cancers, new (targeted) 
drugs, combination with radiotherapy and again improvement in transplantation are responsible 
for the impact on prognosis [18]. Survival also improved for some groups of sarcoma (viscera, 
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trunk and limbs) for which multidisciplinary approaches and centralization of treatments may take 
the credit. This may also be true for neuroendocrine tumors [19], biliary tract, liver [20] and 
esophageal cancers [15], for which there are now more specific and effective 
treatments/protocols. For esophageal cancers, earlier detection through Barrett's esophagus 
surveillance practices might also contribute. For oropharyngeal cancers, the larger proportion of 
less aggressive tumors attributed to HPV may have influenced the survival gain [21]. For 
carcinoma of the thyroid and infiltrating ductal carcinoma of the prostate, early diagnosis should 
be the major factor. This would also have contributed to a rise in the proportion of cases that are 
clinically irrelevant, though this is hard to estimate [12, 22]. As found for incidence, some of the 
apparent survival gains may be due to classification changes [9], such as for large cell 
carcinomas of the lung.  
Myeloproliferative neoplasms and myelodysplastic syndromes were not considered cancers until 
the WHO classification was changed in 2001, and their registration started even later [9]. More in 
general, the increases in incidence of some rare cancers could be due to more specific diagnosis 
and coding by registry.  
The hospital volume analysis represents the first attempt to systematically study the place of 
treatment of rare cancers from population-based CR data. Many potentially relevant indications 
can be drawn from this seldom used source of information. However, several important limitations 
must be recognized. Seven CRs cannot be considered as statistically representative of the whole 
European population. Bulgaria, Finland and Navarra only provided information on, at most, three 
treatments: the first surgical, systemic and radiotherapy treatments. However, we estimated from 
the data of the other CRs that this problem only regard  about 1% of all patients.  
The mean admission volume estimates, based on individual patient data and blind administrative 
coding of hospitals, will depend on how cancer services were organized and coded. We cannot 
know if, for some rare cancers and in some countries, hospitals were linked in organized 
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networks during the study period, thus overcoming an apparent dispersion of treating structures. 
For example, patients with localised sarcomas or head and neck cancers were more frequently 
treated by small and/or peripheral hospitals [23]. If several hospitals provided different services 
but acted co-operatively as a single specialist center, their estimated volume will depend on 
whether they were identified as a single or separate units.  Our data do not allow identifying in 
detail specific protocols used in the considered hospitals. Hospital volume can be therefore 
considered as an only partial quality indicator, mainly pointing to level of experience in protocol 
application and general management of  rare cancer patients.   
 
There are several suggestions that centralization of care improves outcome for rare cancers [24]. 
This is particularly true when optimal treatment requires complex surgery or high-technology 
radiotherapy equipment. It is beyond the scope of this paper to address the volume-survival 
relationship. Diagnosis and treatment in reference centers are expected to be more accurate 
because they benefit from large numbers of cases, which are often discussed in a 
multidisciplinary setting involving expert professionals. Often centralized sites are connected to 
research centers participating in international debates and research. Disadvantages of 
centralization are the need for patients to move and the risk of a longer waiting list, with 
consequent discomfort and possible negative effects on outcome [25].  
Sometimes, centralisation was only moderately perceived by oncologists as a solution to be 
endorsed for rare cancer patients.[26]  
 
For many of the solid rare cancers, centralization did not seem to have been completely achieved 
during the study period. However, most cases had been diagnosed more than ten years ago 
when centralization for cancer patients did not necessarily have much priority. Centralization 
seemed to be more widely implemented for rare cancers requiring highly specific technologies 
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(particularly radiotherapy and nuclear medicine) and for those with long-established evidence-
based guidelines for diagnosis and treatment.  
This was the case for many pediatric tumors, uveal melanoma, anal canal cancers, adrenal 
cortex cancers and, for specific surgical expertise, in CNS cancers and bone sarcomas.  
The degrees of centralization varied across Europe, and to a large extent were affected by the 
population size. In countries with a small population it is easier to concentrate patients in a single 
or few hospitals. High admission volumes are more likely to be achieved in reference centers in 
larger-population countries.  
The results of this part of the study were discussed in the participating countries at dedicated 
meetings attended by public health planners, oncologists, surgeons, representatives of Ministries 
of Health and patient associations. While the general pattern of dispersion was recognised, 
almost all the countries were working at different levels to implement centralization and/or 
network-based organizations for treatment, while still following country-specific priorities [27].  
In Belgium, where all cancer patients can be treated in any hospital with an oncology care 
program, the level of centralization was low. A plan is now under way for the development of 
hospital networks between centers of expertise and other oncology care services/programs. 
Centralization was already ongoing in the Netherlands, mostly for surgical treatment. This was 
reflected in the high admission volumes in this country for many rare cancers (see appendix p 1).  
In Bulgaria rare cancer patients were operated in all hospitals with surgical departments, while 
radiotherapy was concentrated in 17 centers and systemic therapy in 14 oncological hospitals. A 
major issue remains the quality of diagnosis, mainly due to inadequate facilities to diagnose many 
complex rare cancers. The definition of national and international pathways for second opinions 
from expert pathologists was deemed important. With this in mind, the European Reference 
Networks should offer a good opportunity to improve pathologist training through dedicated 
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training schemes and fellowships across Europe. Cancer registration remains vital for monitoring 
progress in rare cancer diagnosis and treatment for these patients. 
In Finland, more than 60% of rare cancer patients were treated in five university hospitals. 
Centralization in single national structures was only observed for uveal melanoma and 
retinoblastoma. Further centralization for other rare cancers is impeded by the spread of the 
population over large areas and by administrative constraints on regional health authorities for 
referring cancer patients to the closest university hospital. 
Irish public health authorities, during the period covered by the study, identified, a few centers  to 
treat rare or particularly complex cancers. However, patients were not always correctly referred to 
them. This highlights the need for strong political commitment to ensure centralization, to make 
sure all rare cancer patients receive the highest quality of care.  
Cancer care was highly centralized in Slovenia. In addition, the major hospitals were organized 
on a task-specific basis: radiotherapy was only provided by the National Cancer Center, while 
surgical treatment was more often done in two other major hospitals. Reducing delays in 
diagnosis and treatment was recognized in Slovenia as one of the major challenges in order to 
improve rare cancer outcomes. 
Navarra is a relatively small region of Spain, a country with a highly regionalized health 
organisation. No hospital with national recruitment for rare cancers was operating in Navarra, and 
98% of resident rare cancer patients were treated locally, the majority in the two largest regional 
hospitals. However, the admission volumes of Navarra hospitals are much lower than in all the 
other participating countries, even considering some underestimation due to unregistered patients 
coming from outside the region. This suggests some disadvantages in organizing rare cancer 
treatment on a regional/local basis. 
To conclude, this is the largest study that estimates the burden of rare cancer for Europe, 
including trends in incidence and survival rates. It also provides indicators of rare cancer 
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treatment management. In seven European countries we observed - with few exceptions - a low 
level of centralization of treatment for rare cancers. We recognise the importance of population-
based cancer registries in descriptive studies like this, to ensure surveillance. However, the 
quality of the data needs to be improved when morphology, hospital and treatment definitions are 
considered. To this aim, the use of specific data quality indicators, the planning of periodic 
sample-based quality studies and, above all, a wider use of these variables in population based 
studies, with related sensitivity analysis, can be suggested. Furthermore, the international 
classification for cancer have to rapidly include the new entities based on molecular and genomic 
categorization. The latter is a necessary condition for updating a new rare cancers list. 
The European network of cancer registries (ENCR) should work to boost these quality 
improvements and make wider use of the data on rare cancers. The Joint Action of Rare Cancers 
[28] and the European Network for Rare Diseases will profit from these data, which are also 
useful for national and European policies to organize care for rare cancer patients better. The 
RARECAREnet project website includes a search tool with data for all the countries that 
contributed data [3]. 
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Table 1. Estimates of incidence and survival  for rare and common cancers, together with expected number of new cases                   
                        
  
Family Cancer entity 
Crude 
Incidence 
Rate per 
100,000 
per year 
95% 
Confidence 
Interval               
lower upper 
Number 
of 
observed 
cases in 
83 CRs 
in 2000-
2007 
Estimated 
new cases   
at 2013 in 
EU (28) 
Five-year 
relative 
survival 
(%) 
95% 
Confidence 
Interval                      
lower upper 
Number 
of 
observed 
cases in 
94 CRs in 
2000-
2007 
RARE 
CANCERS   
            
        
  
Head and neck 
cancers 
  18.82 16.76 16.89 263,565 84,989 52.1 51.8 52.3 254,563 
    EPITHELIAL TUMOURS OF NASAL CAVITY AND SINUSES 0.45 0.44 0.46 7,046 2,282 47.3 45.8 48.8 6,867 
    Squamous cell carcinoma with variants of nasal cavity and sinuses 0.35 0.34 0.36 5,465 1,770 49.5 47.8 51.2 5,444 
    Lymphoepithelial carcinoma of nasal cavity and sinuses 0.00 0.00 0.00 31 10 70.8 50.7 99.0 31 
    Undifferentiated carcinoma of nasal cavity and sinuses 0.02 0.02 0.02 286 93 30.5 24.3 38.2 283 
    Intestinal type adenocarcinoma of nasal cavity and sinuses 0.00 0.00 0.00 42 14 65.0 48.9 86.4 42 
    EPITHELIAL TUMOURS OF NASOPHARYNX 0.47 0.46 0.49 7,439 2,580 48.9 47.5 50.2 7,276 
    Squamous cell carcinoma with variants of nasopharynx 0.36 0.35 0.37 5,613 1,941 48.5 47.0 50.1 5,589 
    Papillary adenocarcinoma of nasopharynx 0.00 0.00 0.00 17 6 58.7 36.2 95.3 17 
  
  
EPITHELIAL TUMOURS OF MAJOR SALIVARY GLANDS 
AND SALIVARY-GLAND TYPE TUMOURS 
1.39 1.37 1.41 21,794 7,059 62.8 62.0 63.7 21,364 
    Epithelial tumours of major salivary glands 0.96 0.95 0.98 15,053 4,876 60.8 59.8 61.8 14,703 
    Salivary gland type tumours of head and neck 0.43 0.42 0.44 6,741 2,183 67.1 65.7 68.6 6,683 
    EPITHELIAL TUMOURS OF HYPOPHARYNX AND LARYNX 6.33 6.29 6.37 99,176 31,545 52.0 51.6 52.4 96,793 
    Squamous cell carcinoma with variants of hypopharynx 1.27 1.25 1.28 19,828 6,422 25.1 24.4 25.9 19,878 
    Squamous cell carcinoma with variants of larynx 4.61 4.58 4.64 72,210 23,389 60.5 60.1 61.0 71,928 
    EPITHELIAL TUMOURS OF OROPHARYNX 3.32 3.29 3.35 52,017 16,848 40.9 40.4 41.4 50,843 
    Squamous cell carcinoma with variants of oropharynx 3.12 3.09 3.14 48,812 15,810 41.3 40.8 41.8 48,401 
    EPITHELIAL TUMOURS OF ORAL CAVITY AND LIP 4.78 4.75 4.81 74,890 24,257 56.7 56.2 57.1 73,101 
    Squamous cell carcinoma with variants of oral cavity 3.51 3.48 3.54 54,931 17,792 48.0 47.5 48.6 54,229 
    Squamous cell carcinoma with variants of lip 1.02 1.00 1.04 15,984 5,177 89.5 88.5 90.5 15,899 
    EPITHELIAL TUMOURS OF EYE AND ADNEXA 0.04 0.04 0.05 679 247 80.6 75.9 85.6 673 
    Squamous cell carcinoma with variants of eye and adnexa 0.03 0.02 0.03 421 136 88.9 83.0 95.2 422 
    Adenocarcinoma with variants of eye and adnexa 0.01 0.01 0.01 134 43 58.7 49.1 70.1 134 
    EPITHELIAL TUMOURS OF MIDDLE EAR 0.03 0.03 0.04 524 170 44.1 38.5 49.6 488 
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    Squamous cell carcinoma with variants middle ear 0.02 0.02 0.03 377 122 37.6 31.8 44.4 370 
    Adenocarcinoma with variants of middle ear 0.00 0.00 0.00 50 16 83.8 70.5 99.5 50 
  
Digestive rare 
cancers 
  21.94 21.86 22.01 343,635 112,351 15.3 15.2 15.5 321,375 
    EPITHELIAL TUMOURS OF OESOPHAGUS 7.81 7.77 7.85 122,344 40,068 11.98 11.8 12.2 119,522 
    Squamous cell carcinoma with variants of oesophagus 3.36 3.33 3.39 52,597 17,036 11.7 11.3 12.0 53,225 
    Adenocarcinoma with variants of oesophagus 3.26 3.24 3.29 51,138 16,564 13.9 13.5 14.2 51,250 
    Salivary gland type tumours of oesophagus 0.00 0.00 0.01 63 20 13.7 6.4 29.0 64 
    Undifferentiated carcinoma of oesophagus 0.04 0.04 0.05 695 225 6.8 4.9 9.4 712 
    RARE EPITHELIAL TUMOURS OF STOMACH 0.33 0.32 0.34 5,146 1,886 15.9 14.7 17.1 5,157 
    Squamous cell carcinoma with variants of stomach 0.12 0.11 0.12 1,807 585 17.5 15.6 19.7 1,800 
    Salivary gland-type tumours of stomach 0.00 0.00 0.00 39 13 25.1 12.7 49.9 40 
    Undifferentiated carcinoma of stomach 0.21 0.20 0.22 3,300 1,069 14.9 13.5 16.4 3,317 
    EPITHELIAL TUMOURS OF SMALL INTESTINE 0.77 0.76 0.79 12,132 3,930 27.3 26.3 28.3 11,544 
    Adenocarcinoma with variants of small intestine 0.59 0.58 0.60 9,219 2,986 27.9 26.8 29.0 9,193 
    Squamous cell carcinoma with variants of small intestine 0.01 0.01 0.01 133 43 34.8 26.8 45.3 133 
    RARE EPITHELIAL TUMOUR OF COLON 0.13 0.13 0.14 2,074 737 54.8 52.0 57.7 2,075 
    Squamous cell carcinoma with variants of colon 0.03 0.02 0.03 400 130 37.1 31.8 43.4 395 
    Fibromixoma and low grade mucinous adenocarcinoma of the appendix 0.11 0.10 0.11 1,674 542 58.8 55.7 62.1 1,680 
    RARE EPITHELIAL TUMOURS OF RECTUM 0.11 0.11 0.12 1,764 635 47.2 44.4 50.2 1,777 
    Squamous cell carcinoma with variants of rectum 0.11 0.11 0.12 1,764 571 47.2 44.4 50.2 1,777 
    EPITHELIAL TUMOURS OF ANAL CANAL 1.16 1.14 1.18 18,155 5,880 56.5 55.5 57.4 18,020 
    Squamous cell carcinoma with variants of anal canal 0.81 0.80 0.82 12,691 4,111 63.0 61.9 64.1 12,847 
    Adenocarcinoma with variants of anal canal 0.25 0.25 0.26 3,970 1,286 41.9 39.9 43.9 3,945 
    Paget s disease of anal canal 0.00 0.00 0.00 21 7 62.9 38.0 104.0 21 
    RARE EPITHELIAL TUMOURS OF PANCREAS 0.07 0.07 0.08 1,159 414 20.2 17.4 23.3 1,116 
    Squamous cell carcinoma with variants of  pancreas 0.02 0.02 0.03 361 117 5.9 3.6 9.6 347 
    Acinar cell carcinoma of pancreas 0.03 0.03 0.03 449 145 19.0 14.8 24.3 427 
    Mucinous cystadenocarcinoma of pancreas 0.01 0.01 0.01 109 35 35.9 26.3 49.0 106 
    Intraductal papillary mucinous carcinoma invasive of pancreas 0.01 0.01 0.01 173 56 31.8 23.6 42.9 171 
    Solid pseudopapillary carcinoma of pancreas 0.00 0.00 0.00 44 14 67.7 52.8 86.8 42 
    Serous cystadenocarcinoma of pancreas 0.00 0.00 0.00 4 1 NE NE NE 4 
    Carcinoma with osteoclast-like giant cells of  pancreas 0.00 0.00 0.00 19 6 NE NE NE 19 
  
  
EPITHELIAL TUMOURS OF LIVER AND INTRAEPATIC 
BILE TRACT (IBT) 
7.10 7.06 7.14 111,271 36,261 10.1 9.9 10.3 98,765 
    Hepatocellular carcinoma of Liver and IBT 3.22 3.19 3.25 50,461 16,344 14.0 13.7 14.4 46,896 
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    Hepatocellular carcinoma, fibrolamellar of liver and IBT 0.02 0.02 0.03 387 125 28.1 23.3 33.8 390 
    Cholangiocarcinoma of IBT 0.97 0.95 0.99 15,201 4,924 6.0 5.6 6.6 13,845 
    Adenocarcinoma with variants of liver and IBT 0.41 0.40 0.42 6,457 2,091 6.6 5.9 7.4 6,311 
    Undifferentiated carcinoma of liver and IBT 0.02 0.01 0.02 240 78 2.7 1.2 6.4 219 
    Squamous cell carcinoma with variants of liver and IBT 0.01 0.01 0.01 147 48 14.6 9.1 23.4 143 
    Bile duct cystadenocarcinoma of IBT 0.00 0.00 0.00 38 12 23.6 11.5 48.5 34 
  
  
EPITHELIAL TUMOURS OF GALLBLADDER AND 
EXTRAHEPATIC BILIARY TRACT (EBT) 
4.44 4.41 4.48 69,590 22,540 13.6 13.2 13.9 63,889 
    Adenocarcinoma with variants of gallbladder 1.35 1.33 1.36 21,085 6,830 14.5 14.0 15.1 20,338 
    Adenocarcinoma with variants of EBT 1.44 1.42 1.46 22,510 7,291 19.2 18.6 19.8 22,234 
    Squamous cell carcinoma of gallbladder and EBT 0.03 0.03 0.03 496 161 8.8 6.3 12.3 476 
  
Thoracic rare 
cancers 
  6.80 6.76 6.84 106,573 37,277 13.4 13.1 13.6 104,670 
    EPITHELIAL TUMOUR OF TRACHEA 0.11 0.11 0.12 1,771 574 18.0 16.0 20.3 1,697 
    Squamous cell carcinoma with variants of trachea 0.06 0.06 0.07 1,017 329 12.2 10.0 14.9 1,008 
    Adenocarcinoma with variants of trachea 0.01 0.01 0.01 164 53 15.7 10.3 24.0 158 
    Salivary gland type tumours of trachea 0.01 0.01 0.01 175 57 70.1 62.0 79.2 174 
    RARE EPITHELIAL TUMOUR OF LUNG 4.37 4.34 4.40 68,452 24,930 14.9 14.6 15.2 67,936 
    Adenosquamous carcinoma of lung 0.29 0.29 0.30 4,607 1,492 21.9 20.5 23.4 4,566 
    Large cell carcinoma of lung 3.81 3.78 3.84 59,714 19,342 13.9 13.5 14.2 59,332 
    Salivary gland type tumours of lung 0.06 0.05 0.06 879 285 40.4 36.8 44.4 866 
    Sarcomatoid carcinoma of lung 0.21 0.20 0.22 3,255 1,054 17.5 16.0 19.2 3,183 
    EPITHELIAL TUMOURS OF THYMUS 0.18 0.17 0.19 2,795 905 64.3 62.1 66.6 2,729 
    Malignant thymoma 0.14 0.14 0.15 2,268 735 69.3 67.0 71.8 2,248 
    Squamous cell carcinoma of thymus 0.01 0.01 0.01 114 37 40.4 30.4 53.7 112 
    Undifferentiated carcinoma of thymus 0.00 0.00 0.00 36 12 13.3 5.1 34.8 36 
    Lymphoepithelial carcinoma of thymus 0.00 0.00 0.00 12 4 55.0 29.2 103.6 11 
    Adenocarcinoma with variants of thymus 0.00 0.00 0.00 45 15 37.3 21.7 64.1 44 
    MALIGNANT MESOTHELIOMA 2.14 2.12 2.16 33,552 10,868 5.3 4.9 5.6 32,330 
    Mesothelioma of pleura and pericardium 1.83 1.81 1.85 28,676 9,288 4.6 4.2 4.9 27,893 
    Mesothelioma of peritoneum and tunica vaginalis 0.13 0.13 0.14 2,065 669 13.2 11.5 15.1 1,965 
  
Female genital 
rare cancers 
  22.73 22.66 22.81 356,151 113,796 57.7 57.5 57.9 347,015 
    RARE EPITHELIAL TUMOURS OF BREAST 4.12 4.09 4.16 64,605 22,980 91.4 91.0 91.8 64,368 
    Mammary Paget’s disease of breast 0.41 0.40 0.42 6,488 2,101 85.9 84.6 87.3 6,508 
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    Special types of adenocarcinoma of breast 3.06 3.04 3.09 48,012 15,551 95.2 94.8 95.6 47,974 
    Metaplastic carcinoma of breast 0.10 0.10 0.11 1,576 510 65.0 61.9 68.3 1,583 
    Salivary gland type tumours of breast 0.06 0.05 0.06 868 281 90.9 87.6 94.2 870 
    Epithelial tumour of male breast 0.52 0.51 0.53 8,098 5,376 77.0 75.5 78.5 7,882 
    RARE EPITHELIAL TUMOURS OF CORPUS UTERI 0.70 0.69 0.72 11,038 3,932 44.3 43.2 45.5 11,013 
    Squamous cell carcinoma with variants of corpus uteri 0.06 0.06 0.07 1,003 325 58.2 54.6 62.1 989 
    Adenoid cystic carcinoma of corpus uteri 0.00 0.00 0.00 5 2 64.1 31.3 131.1 5 
    Clear cell adenocarcinoma, NOS of corpus uteri 0.16 0.16 0.17 2,527 819 58.6 56.2 61.2 2,532 
    Serous (papillary) carcinoma of corpus uteri 0.08 0.07 0.08 1,227 397 40.0 36.5 43.9 1,225 
    Mullerian mixed tumour of corpus uteri 0.40 0.39 0.41 6,276 2,033 36.9 35.5 38.4 6,263 
    EPITHELIAL TUMOURS OF CERVIX UTERI 6.28 6.24 6.32 98,321 28,898 65.4 65.1 65.8 96,821 
    Squamous cell carcinoma with variants of cervix uteri 4.73 4.70 4.76 74,105 24,003 66.8 66.5 67.2 73,810 
    Adenocarcinoma with variants of cervix uteri 0.91 0.89 0.92 14,252 4,616 67.4 66.5 68.3 14,221 
    Undifferentiated carcinoma of cervix uteri 0.03 0.03 0.03 480 155 35.3 30.9 40.4 478 
    Mullerian mixed tumour of cervix uteri 0.02 0.01 0.02 257 83 34.3 28.1 41.7 256 
    EPITHELIAL TUMOUR OF OVARY AND FALLOPPIAN TUBE 9.38 9.33 9.43 146,908 45,382 37.5 37.2 37.8 141,240 
    Adenocarcinoma with variants of ovary 5.95 5.92 5.99 93,263 30,208 38.7 38.3 39.1 92,814 
    Mucinous adenocarcinoma of ovary 0.77 0.76 0.78 12,066 3,908 59.9 58.9 60.9 12,010 
    Clear cell adenocarcinoma of ovary 0.30 0.29 0.31 4,753 1,540 55.5 53.8 57.2 4,761 
    Primary peritoneal serous/papillary carcinoma of ovary 0.08 0.08 0.09 1,280 415 21.9 19.1 25.2 1,280 
    Mullerian mixed tumour of ovary 0.14 0.14 0.15 2,255 730 21.4 19.5 23.6 2,242 
    Adenocarcinoma with variant of falloppian tube 0.17 0.16 0.18 2,683 869 59.1 56.8 61.6 2,672 
    NON EPITHELIAL TUMOURS OF OVARY 0.25 0.25 0.26 3,977 1,288 82.0 80.6 83.5 3,970 
    Sex cord tumours of ovary 0.13 0.12 0.13 2,006 650 78.8 76.5 81.1 1,998 
    Malignant/Immature teratomas of ovary 0.05 0.05 0.06 833 270 83.4 80.6 86.3 829 
    Germ cell tumour of ovary 0.07 0.07 0.08 1,138 369 86.6 84.4 88.8 1,143 
    EPITHELIAL TUMOURS OF VULVA AND VAGINA 1.97 1.95 2.00 30,938 11,215 58.1 57.3 58.8 30,238 
    Squamous cell carcinoma with variants of vulva and vagina 1.69 1.67 1.71 26,422 8,558 59.8 59.0 60.7 26,277 
    Adenocarcinoma with variants of vulva and vagina 0.07 0.07 0.08 1,120 363 45.8 42.3 49.6 1,112 
    Paget s disease of vulva and vagina 0.05 0.04 0.05 746 242 88.0 83.7 92.6 744 
    Undifferentiated carcinoma of vulva and vagina 0.01 0.00 0.01 85 28 25.6 15.8 41.6 85 
    TROPHOBLASTIC TUMOUR OF PLACENTA 0.02 0.02 0.03 363 100 89.3 85.3 92.2 361 
    Choriocarcinoma of placenta 0.02 0.02 0.02 352 114 89.8 86.5 93.3 350 
  
Male genital 
and urogenital 
rare cancers 
  7.09 7.05 7.14 111,128 38,138 73.64 73.3 74.0 109,102 
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    RARE EPITHELIAL TUMOURS OF PROSTATE 0.60 0.59 0.61 9,437 3,563 75.4 74.0 76.9 9,291 
    Squamous cell carcinoma with variants of prostate 0.02 0.02 0.02 291 94 41.1 34.1 49.5 287 
    Infiltrating duct carcinoma of prostate 0.51 0.50 0.53 8,064 2,612 78.7 77.2 80.3 7,945 
    Transitional cell carcinoma of prostate 0.06 0.06 0.07 960 311 57.7 53.4 62.4 941 
    Salivary gland type tumours of prostate 0.01 0.01 0.01 122 40 78.5 64.4 95.7 118 
    TESTICULAR AND PARATESTICULAR CANCERS 3.29 3.27 3.32 51,605 16,061 94.9 94.7 95.2 51,011 
    Paratesticular adenocarcinoma with variants 0.00 0.00 0.00 22 7 82.5 65.3 104.1 22 
    Non seminomatous testicular cancer 1.27 1.25 1.28 19,835 6,425 92.9 92.5 93.3 19,714 
    Seminomatous testicular cancer 1.82 1.80 1.84 28,516 9,236 97.5 97.3 97.8 28,326 
    Spermatocytic seminoma 0.03 0.03 0.03 502 163 95.3 91.8 99.0 502 
    Teratoma with malignant transformation 0.00 0.00 0.00 20 6 91.4 78.6 106.2 20 
    Testicular sex cord cancer 0.02 0.02 0.02 340 110 82.3 77.3 87.6 337 
    EPITHELIAL TUMOURS OF PENIS 0.66 0.65 0.67 10,368 3,887 67.5 66.2 68.9 10,210 
    Squamous cell carcinoma with variants of penis 0.62 0.60 0.63 9,646 3,124 68.9 67.5 70.2 9,621 
    Adenocarcinoma with variants of penis 0.01 0.00 0.01 88 29 49.0 36.2 66.4 86 
    RARE EPITELIAL TUMOURS OF KIDNEY 0.05 0.04 0.05 723 261 18.8 15.8 22.4 704 
    Squamous cell carcinoma spindle cell type of kidney 0.01 0.01 0.01 190 62 22.0 16.0 30.2 190 
    Squamous cell carcinoma with variants of kidney 0.03 0.03 0.04 533 173 17.7 14.4 21.7 514 
    EPITHELIAL TUMOURS OF PELVIS AND URETER 1.58 1.57 1.60 24,826 9,187 48.8 48.0 49.7 24,017 
    Transitional cell carcinoma of pelvis and ureter 1.41 1.39 1.43 22,099 7,158 51.3 50.4 52.2 21,607 
    Squamous cell carcinoma with variants of pelvis and ureter 0.02 0.02 0.03 372 121 15.0 11.2 20.2 366 
    Adenocarcinoma with variants of pelvis and ureter 0.02 0.02 0.02 326 106 43.0 36.7 50.5 320 
    EPITHELIAL TUMOURS OF URETHRA 0.13 0.13 0.14 2,077 784 44.5 41.6 47.5 2,050 
    Transitional cell carcinoma of urethra 0.09 0.08 0.09 1,390 450 42.9 39.5 46.7 1,387 
    Squamous cell carcinoma with variants of urethra 0.02 0.02 0.02 329 107 51.1 44.6 58.5 329 
    Adenocarcinoma with variants of urethra 0.01 0.01 0.01 190 62 52.0 43.2 62.6 189 
    RARE EPITHELIAL TUMOURS OF BLADDER 0.65 0.64 0.67 10,226 3,819 32.3 31.2 33.5 10,152 
    Squamous cell carcinoma with variants of bladder 0.36 0.35 0.36 5,566 1,803 24.3 22.9 25.7 5,534 
    Adenocarcinoma with variants of bladder 0.30 0.29 0.31 4,653 1,507 41.9 40.1 43.8 4,614 
    Salivary gland type tumours of bladder 0.00 0.00 0.00 7 2 NE NE NE 7 
    EXTRAGONADAL GERM CELL TUMOURS 0.12 0.11 0.12 1,862 576 69.6 67.3 71.8 1,851 
    Non seminomatous germ cell tumours 0.06 0.05 0.06 915 296 62.5 59.2 66.0 909 
    Seminomatous germ cell tumors 0.01 0.01 0.01 130 42 85.9 79.1 93.3 130 
    Germ cell tumors of CNS 0.04 0.03 0.04 574 186 82.5 79.2 85.9 572 
  
Neuroendocrine 
tumours 
  3.51 3.43 3.58  54,942 19,587 53.5 53.0 54.1 54,331 
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    NEUROENDOCRINE TUMOURS 3.51 3.48 3.54 54,942 19,587 53.5 53.0 54.1 54,331 
  
  
GEP, well diff not funct endocrine carcinoma of pancreas and digestive 
tract 
1.01 1.00 1.03 15,852 5,134 72.0 71.1 73.0 15,656 
  
  
GEP, well diff funct endocrine carcinoma of pancreas and digestive 
tract 
0.03 0.02 0.03 411 133 61.3 55.9 67.3 407 
    GEP, poorly differentiated endocrine carcinoma 0.67 0.65 0.68 10,421 3,375 35.0 33.9 36.2 10,456 
    GEP, mixed endocrine-exocrine carcinoma 0.01 0.01 0.01 147 48 25.9 18.2 37.0 141 
    Endocrine carcinoma of thyroid gland 0.24 0.23 0.25 3,796 1,230 83.6 82.1 85.2 3,793 
    Neuroendocrine carcinoma of skin 0.19 0.19 0.20 3,024 979 55.9 53.2 58.7 2,997 
    Typical and atypical carcinoid of the lung 0.39 0.38 0.40 6,160 1,995 81.1 79.9 82.5 6,058 
    Neuroendocrine carcinoma of other sites 0.90 0.89 0.92 14,120 4,573 23.9 23.0 24.8 13,958 
    Pheochromocytoma, malignant 0.04 0.04 0.04 650 211 70.1 65.9 74.5 612 
    Paraganglioma 0.02 0.02 0.02 347 112 56.3 50.6 62.6 342 
  
Cancers of the 
endocrine 
organs 
  5.35 5.32 5.39 83,836 28,322 88.08 87.8 88.4 82,523 
    CARCINOMAS OF PITUITARY GLAND 0.04 0.03 0.04 582 206 63.7 58.9 69.0 511 
    Carcinoma of pituitary gland 0.04 0.03 0.04 582 206 63.7 58.9 69.0 511 
    CARCINOMAS OF THYROID GLAND 5.07 5.03 5.10 79,418 26,768 90.5 90.2 90.8 78,533 
    Carcinoma of thyroid gland 5.07 5.03 5.11 79,420 26,768 90.5 90.2 90.8 78,533 
    CARCINOMAS OF PARATHYROID GLAND 0.03 0.02 0.03 410 143 80.8 75.8 86.2 395 
    Carcinoma of parathyroid gland 0.03 0.02 0.03 410 143 80.8 75.8 86.2 395 
    CARCINOMA OF ADRENAL GLAND 0.22 0.21 0.23 3,424 1,205 32.1 30.2 34.0 3,103 
    Carcinoma of adrenal gland 0.22 0.21 0.23 3,424 1,205 32.1 30.2 34.0 3,103 
  Sarcomas   5.86 5.83 6.00 91,878 31,916 59.53 57.4 58.2 90,568 
    SOFT TISSUE SARCOMA 4.71 4.68 4.74 73,795 25,851 56.7 56.3 57.1 72,696 
    Soft tissue sarcoma of head and neck 0.26 0.25 0.27 4,087 1,324 59.8 57.7 61.8 4,062 
    Soft tissue sarcoma of limbs 1.10 1.08 1.11 17,178 5,564 67.7 66.8 68.6 17,094 
    Soft tissue sarcoma of superficial trunk 0.50 0.49 0.51 7,813 2,531 48.1 46.8 49.5 7,723 
    Soft tissue sarcoma of mediastinum 0.03 0.03 0.03 465 151 23.4 19.3 28.3 457 
    Soft tissue sarcoma of heart 0.01 0.01 0.02 216 70 14.4 9.8 21.0 203 
    Soft tissue sarcoma of breast 0.18 0.18 0.19 2,865 928 74.5 72.5 76.5 2,864 
    Soft tissue sarcoma of uterus 0.55 0.54 0.56 8,657 2,804 52.0 50.8 53.2 8,568 
    Other soft tissue sarcomas of genitourinary tract 0.20 0.19 0.21 3,160 1,024 50.4 48.3 52.5 3,107 
    Soft tissue sarcoma of viscera 0.38 0.37 0.39 6,004 1,945 42.1 40.6 43.6 5,915 
    Soft tissue sarcoma of paratestis 0.03 0.03 0.04 510 165 87.2 82.2 92.4 510 
    Soft tissue sarcoma of retroperitoneum and peritoneum 0.31 0.30 0.32 4,911 1,591 38.8 37.1 40.5 4,854 
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    Soft tissue sarcoma of pelvis 0.20 0.19 0.20 3,090 1,001 47.4 45.3 49.6 3,064 
    Soft tissue sarcoma of skin 0.30 0.29 0.31 4,737 1,534 90.2 88.8 91.7 4,728 
    Soft tissue sarcoma of paraorbit 0.01 0.01 0.01 117 38 63.3 52.9 75.7 115 
    Soft tissue sarcoma of brain and other parts of nervous system 0.17 0.17 0.18 2,723 882 54.5 52.3 56.7 2,695 
    Embryonal rhabdomyosarcoma of soft tissue 0.05 0.05 0.06 836 271 66.2 62.8 69.8 825 
    Alveolar rhabdomyosarcoma of soft tissue 0.03 0.03 0.04 519 168 36.0 31.7 40.8 515 
    Ewing’s sarcoma of soft tissue 0.06 0.06 0.07 998 323 44.9 41.5 48.5 992 
    BONE SARCOMA 0.85 0.84 0.87 13,376 4,382 58.6 57.6 59.6 13,216 
    Osteogenic sarcoma 0.21 0.21 0.22 3,330 1,079 51.4 49.5 53.4 3,282 
    Chondrogenic sarcomas 0.26 0.25 0.27 4,107 1,330 70.0 68.2 71.7 4,060 
    Notochordal sarcomas, chordoma 0.07 0.07 0.08 1,145 371 62.5 58.2 67.2 755 
    Vascular sarcomas 0.01 0.01 0.01 129 42 45.1 36.4 55.9 129 
    Ewing’s sarcoma 0.12 0.12 0.13 1,943 629 52.8 50.4 55.3 1,932 
    Epithelial tumours, adamantinoma 0.01 0.01 0.02 213 69 87.2 81.0 93.9 210 
  
  
Other high grade sarcomas (fibrosarcoma, malignant fibrous 
histiocytoma) 
0.02 0.02 0.02 304 98 46.2 40.1 53.1 302 
    GASTROINTESTINAL STROMAL SARCOMA 0.30 0.29 0.31 4,706 1,683 72.3 70.4 74.1 4,781 
    Gastrointestinal stromal sarcoma 0.30 0.29 0.31 4,706 1,524 72.3 70.4 74.1 4,781 
  
Cancers of the 
central nervous 
system (CNS) 
  7.56 7.51 8.00 118,391 36,343 21.3 21.0 21.6 111,838 
    TUMOURS OF CENTRAL NERVOUS SYSTEM (CNS)** 7.36 7.32 7.40 115,289 35,339 20.3 20.0 20.6 108,752 
    Astrocytic tumours of CNS 4.99 4.95 5.02 78,118 25,303 15.0 14.8 15.3 77,195 
    Oligodendroglial tumours of CNS 0.39 0.38 0.40 6,148 1,991 51.8 50.4 53.3 6,124 
    Ependymal tumours of CNS 0.21 0.20 0.21 3,212 1,040 72.7 71.0 74.5 3,190 
    Choroid plexus carcinoma of CNS 0.01 0.01 0.01 98 32 57.7 48.3 68.8 95 
    Malignant meningiomas 0.16 0.16 0.17 2,564 830 61.1 58.8 63.4 2,509 
    EMBRYONAL TUMORS OF CNS 0.20 0.19 0.21 3,102 1,005 56.1 54.2 58.1 3,092 
    Embryonal tumors of CNS 0.20 0.19 0.21 3,102 1,005 56.1 54.2 58.1 3,092 
  
Rare skin 
cancers and     
non-cutaneous 
melanoma 
  1.22 1.18 1.25 21,878  7,086 70.2 69.3 71.1 21,637 
    MALIGNANT MELANOMA OF MUCOSA 0.15 0.14 0.15 2,279 738 20.3 18.2 22.6 2,277 
    Malignant melanoma of mucosa 0.15 0.14 0.15 2,279 738 20.3 18.3 22.6 2,277 
    MALIGNANT MELANOMA OF UVEA 0.70 0.69 0.72 11,022 3,570 71.0 69.8 72.2 10,872 
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    Malignant melanoma of uvea 0.70 0.69 0.72 11,022 3,570 71.0 69.8 72.2 10,872 
    ADNEXAL CARCINOMA OF SKIN 0.30 0.29 0.31 4,684 1,517 86.1 83.9 88.0 4,661 
    Adnexal carcinoma of skin 0.30 0.29 0.31 4,684 1,517 86.1 83.9 88.0 4,661 
    KAPOSI'S SARCOMA 0.25 0.24 0.26 3,893 1,261 78.9 77.0 80.7 3,830 
    Kaposi's sarcoma 0.25 0.24 0.26 3,893 1,261 78.9 77.1 80.8 3,830 
  
Embrional 
tumours  
  0.34 0.33 0.35 5,363 1,822 78.6 77.4 79.8 5,239 
    NEUROBLASTOMA AND GANGLIONEUROBLASTOMA 0.10 0.10 0.11 1,566 499 64.6 62.1 67.3 1,553 
    Neuroblastoma e ganglioneuroblastoma 0.10 0.10 0.11 1,566 507 64.6 62.1 67.3 1,553 
    NEPHROBLASTOMA 0.13 0.12 0.13 1,965 636 88.2 86.6 89.7 1,936 
    Nephroblastoma 0.13 0.12 0.13 1,965 636 88.2 86.6 89.7 1,936 
    RETINOBLASTOMA 0.05 0.05 0.06 860 279 96.5 95.1 97.9 801 
    Retinoblastoma 0.05 0.05 0.06 860 279 96.5 95.1 97.9 801 
    HEPATOBLASTOMA 0.02 0.02 0.03 357 116 76.8 72.2 81.7 352 
    Hepatoblastoma 0.02 0.02 0.03 357 116 76.8 72.2 81.7 352 
    PLEUROPULMONARY BLASTOMA 0.02 0.02 0.03 357 116 76.8 72.2 81.7 352 
    Pleuropulmonary blastoma 0.00 0.00 0.00 9 3 53.5 28.3 101.1 9 
    PANCREATOBLASTOMA 0.00 0.00 0.00 9 3 53.5 28.3 101.1 9 
    Pancreatoblastoma 0.00 0.00 0.00 39 13 34.3 20.7 56.9 35 
    OLFACTORY NEUROBLASTOMA 0.00 0.00 0.00 39 13 34.3 20.7 56.9 35 
    Olfactory neuroblastoma 0.03 0.03 0.03 498 161 64.0 59.2 69.2 489 
    ODONTOGENIC MALIGNANT TUMOURS 0.03 0.03 0.03 498 161 64.0 59.2 69.2 489 
    Odontogenic malignant tumours 0.00 0.00 0.01 69 22 61.6 49.0 77.5 69 
  
Haematological 
rare 
malignancies 
  27.73 27.65 27.82 434,469 156,099 50.5 50.3 50.7 423,741 
    RARE LYMPHOID DISEASES 18.09 18.02 18.16 283,399 100,343 55.8 55.5 56.0 279,794 
    Hodgkin lymphoma, classical 2.46 2.44 2.49 38,588 12,499 81.4 80.9 81.8 38,389 
    Hodgkin lymphoma nodular lymphocyte predominance 0.09 0.09 0.10 1,483 480 93.6 91.8 95.3 1,507 
  
  
Precursor B/T lymphoblastic leuk/lymphoma (and Burkitt 
leukemia/lymphoma) 
1.46 1.44 1.47 22,795 7,383 58.1 57.4 58.8 22,496 
    T cutaneous lymphoma (Sezary syn, Mycosis fung) 0.35 0.34 0.36 5,526 1,790 81.5 80.0 83.1 5,482 
    Other T cell lymphomas and NK cell neoplasms 0.62 0.60 0.63 9,656 3,128 39.0 37.9 40.2 9,635 
    Diffuse B lymphoma 4.32 4.29 4.35 67,645 21,910 53.4 52.9 53.9 67,907 
    Follicular B lymphoma 2.19 2.17 2.22 34,346 11,125 77.0 76.4 77.6 34,545 
    Hairy cell leukaemia 0.28 0.27 0.29 4,375 1,417 89.8 88.3 91.3 4,387 
    Plasmacytoma/Multiple Myeloma (and Heavy chain diseases) 5.71 5.67 5.75 89,440 28,970 35.3 34.8 35.7 86,496 
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    Mantle cell lymphoma 0.56 0.55 0.57 8,748 2,834 44.0 42.6 45.4 8,797 
    Prolymphocytic leukaemia, B cell 0.05 0.05 0.06 804 260 30.8 26.9 35.2 788 
  
  
ACUTE MYELOID LEUKEMIA AND RELATED PRECURSOR 
NEOPLASMS 
3.81 3.77 3.84 59,608 21,557 
19.2 18.8 19.6 56,709 
    Acute promyelocytic leukemia (AML with t(15;17) with variants 0.12 0.11 0.13 1,876 608 63.2 60.8 65.7 1,880 
    Acute myeloid leukemia 3.50 3.47 3.53 54,789 17,746 17.5 17.1 17.8 52,305 
    MYELOPROLIFERATIVE NEOPLASMS 3.31 3.28 3.34 51,888 18,805 68.3 67.7 68.9 50,624 
    Chronic myeloid leukemia 1.12 1.10 1.13 17,473 5,660 54.9 54.0 55.9 16,599 
    Other myeloproliferative neoplasms 2.17 2.14 2.19 33,954 10,998 75.0 74.3 75.7 33,599 
    Mast cell tumour 0.03 0.03 0.03 461 149 71.4 66.2 77.1 454 
  
  
MYELODYSPLASTIC SYNDROME AND 
MYELODYSPLASTIC/MYELOPROLIFERATIVE DISEASES 
2.47 2.45 2.50 38,738 15,116 31.1 30.5 31.8 37,792 
    Myelodysplastic syndrome with 5q syndrome 0.01 0.01 0.01 156 51 48.0 38.3 60.3 178 
    Other myelodysplastic syndrome 2.14 2.12 2.16 33,542 10,864 32.2 31.5 32.9 32,576 
    Chronic Myelomonocytic leukemia 0.29 0.28 0.30 4,542 1,471 21.3 19.8 23.0 4,575 
    Atypical chronic myeloid leukemia BCR/ABL negative 0.02 0.01 0.02 239 77 28.2 21.7 36.5 248 
    HISTIOCYTIC AND DENDRITIC CELL NEOPLASMS 0.05 0.05 0.06 828 278 59.9 56.1 63.9 817 
    Histiocytic malignancies 0.04 0.04 0.05 656 212 63.4 59.4 67.8 645 
    Lymph node accessory cell tumors 0.01 0.01 0.01 172 56 45.6 37.1 56.0 172 
  
All rare 
tumours 
ALL RARE TIER2 TUMOURS  114.99 114.82 115.16 1,801,443 636,753 48.5 48.4 48.6 1,751,601 
COMMON 
CANCERS 
  
                    
  
Digestive 
common 
tumours 
  91.80 91.65 91.95 1,438,094 490,051 41.4 41.3 45.8 1,365,575 
    EPITHELIAL TUMOURS OF STOMACH 17.10 17.03 17.16 267,832 92,067 21.2 21.0 21.4 253,439 
    Adenocarcinoma with variants of stomach 14.18 14.12 14.24 222,145 71,954 22.7 22.5 22.9 221,604 
    EPITHELIAL TUMOUR OF COLON 43.88 43.77 43.98 687,386 234,319 54.2 54.0 54.4 664,118 
    Adenocarcinoma with variants of colon 38.85 38.75 38.95 608,637 197,139 57.9 57.7 58.0 604,459 
    EPITHELIAL TUMOURS OF RECTUM 17.98 17.92 18.05 281,697 95,187 53.8 53.6 54.1 276,024 
    Adenocarcinoma with variants of rectum 16.45 16.39 16.52 257,723 83,477 55.8 55.6 56.1 258,469 
    EPITHELIAL TUMOURS OF PANCREAS 12.84 12.79 12.90 201,179 68,478 4.1 4.0 4.2 182,579 
    Adenocarcinoma with variants of pancreas 7.96 7.92 8.01 124,744 40,405 4.1 4.0 4.2 119,154 
  
Thoracic 
common 
tumours 
  53.02 52.91 53.14 830,611 281,332 10.1 10.0 10.2 779,539 
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    EPITHELIAL TUMOUR OF LUNG 53.02 52.91 53.14 830,611 281,332 10.1 10.0 10.2 779,539 
    Squamous cell carcinoma with variants of lung 12.31 12.25 12.36 192,771 62,439 5.9 13.7 14.1 121,904 
    Adenocarcinoma with variants of lung 11.63 11.58 11.68 182,175 59,007 40.4 15.9 16.3 866 
    Poorly differentiated endocrine carcinoma of lung 7.91 7.86 7.95 123,888 40,128 17.5 5.7 6.0 3,183 
  
Female genital 
common 
tumours 
  74.17 74.03 74.30 1,161,864 394,087 82.20 82.10 82.30 1,131,902 
    EPITHELIAL TUMOURS OF BREAST 63.52 63.40 63.65 995,119 318,878 82.4 82.3 82.5 971,037 
    Invasive ductal carcinoma of breast 46.56 46.45 46.66 729,345 236,237 85.4 85.3 85.6 723,998 
    Invasive lobular carcinoma of breast 7.75 7.71 7.80 121,455 39,340 86.2 85.9 86.5 120,973 
    EPITHELIAL TUMOURS OF CORPUS UTERI 10.64 10.59 10.70 166,745 75,209 81.2 80.9 81.4 164,787 
    Adenocarcinoma with variants of corpus uteri 9.93 9.88 9.98 155,550 50,383 83.0 82.7 83.2 154,968 
  
Male genital 
and urogenital 
common 
tumours 
  85.27 85.13 85.42 1,335,876 462,665 75.90 75.80 76.00 1,277,743 
    EPITHELIAL TUMOURS OF PROSTATE 55.06 54.95 55.18 862,576 301,113 84.0 83.8 84.1 842,467 
    Adenocarcinoma with variants of prostate 48.86 48.75 48.97 765,405 247,917 88.1 88.0 88.3 762,360 
    EPITELIAL TUMOURS OF KIDNEY 12.66 12.61 12.72 198,402 65,848 60.5 60.2 60.7 187,324 
    Renal cell carcinoma with variants 10.08 10.03 10.13 157,886 51,140 68.5 68.2 68.8 153,460 
    EPITHELIAL TUMOURS OF BLADDER 17.55 17.48 17.61 274,896 95,704 60.4 60.1 60.6 266,941 
    Transitional cell carcinoma of bladder 15.68 15.62 15.74 245,681 79,577 62.7 62.4 63.0 243,620 
                        
  
Common skin 
tumours and 
non-cutaneous 
melanoma 
  69.08 68.95 69.21 1,082,244 350,542 95.6 95.5 95.7 1,048,046 
    MALIGNANT SKIN MELANOMA 14.06 14.00 14.12 220,206 71,325 83.8 83.6 84.0 216,317 
    Malignant skin melanoma 14.06 14.00 14.12 220,206 71,325 83.8 83.6 84.1 216,317 
    EPITHELIAL TUMOURS OF SKIN 55.03 54.91 55.14 862,038 279,217 98.8 98.7 99 837,895 
    Basal cell carcinoma of skin 40.75 40.65 40.85 638,347 206,763 101.6 101.5 101.8 634,953 
    Squamous cell carcinoma with variants of skin 14.28 14.22 14.34 223,691 72,454 89.7 89.4 90.1 221,487 
  
Haematological 
common 
malignancies 
  11.03 10.98 11.08 172,794 58,286 60.5 60.2 60.8 166,040 
    LYMPHOID DISEASES 11.03 10.98 11.08 172,794 58,286 60.5 60.2 60.8 166,040 
    Other non Hodgkin, Mature B cell lymphoma 6.37 6.33 6.41 99,729 32,303 68.3 67.8 68.7 97,389 
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All common 
tumours 
ALL COMMON  384.37 384.07 384.78 6,021,483 2,036,963 63.4 63.3 63.4 5,633,710 
  
Note: the first tier entities (capital letters) are not a sum of the second tiers (small letters) included 
because of the NOS entities 
                
 
NE= not estimable 
          
 
 
 
Table 2. Age standardized incidence (IR) in 1999-2002 and 2003-2007, and corresponding Annual Percent Changes (APC) between the two periods, of rare cancers lying outside the 3-
standard-errors confidence bounds in Figure 1 
Cancer entity 
1999-2002     
IR 
2003-2007 
IR 
APC 
99.8% Confidence interval 
           lower                     upper 
Gastrointestinal stromal sarcoma 0.098 0.258 24.1 12.0 36.2 
GEP, Poorly differentiated endocrine carcinoma of pancreas and digestive system 0.361 0.618 12.7 7.7 17.8 
Other T cell lymphomas and NK cell neoplasms 0.395 0.555 7.8 3.3 12.4 
Diffuse B lymphoma 2.837 3.894 7.3 5.7 8.9 
Other myeloproliferative neoplasms 1.530 2.092 7.2 5.0 9.4 
Mantle cell lymphoma 0.367 0.477 6.0 1.6 10.4 
Carcinomas of thyroid gland 3.470 4.353 5.2 3.7 6.6 
Other myelodysplastic syndrome 1.395 1.738 5.0 3.0 7.1 
Squamous cell carcinoma with variants of anal canal 0.595 0.728 4.6 1.2 8.0 
Follicular B lymphoma 1.676 2.021 4.2 2.2 6.3 
Cholangiocarcinoma of IBT 0.685 0.816 4.0 0.9 7.0 
Neuroendocrine carcinoma of other sites 0.683 0.801 3.6 0.5 6.7 
Adenocarcinoma with variants of oesophagus 2.725 3.153 3.3 1.8 4.8 
Squamous cell carcinoma with variants of oropharynx 2.412 2.732 2.8 1.1 4.5 
Adenocarcinoma with variants of EBT 0.969 1.088 2.6 0.1 5.1 
Hepatocellular carcinoma of Liver and IBT 2.068 2.273 2.1 0.4 3.8 
Squamous cell carcinoma with variants of cervix uteri 4.536 4.287 -1.2 -2.4 -0.1 
Adenocarcinoma with variants of ovary 5.351 5.053 -1.3 -2.3 -0.2 
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Squamous cell carcinoma with variants of larynx 3.853 3.578 -1.6 -2.8 -0.4 
Chronic myeloid leukemia 0.991 0.854 -3.2 -5.5 -0.9 
Infiltrating duct carcinoma of prostate 0.412 0.343 -4.0 -7.4 -0.6 
Squamous cell carcinoma with variants of lip 0.838 0.693 -4.1 -6.5 -1.8 
Large cell carcinoma of lung 3.440 2.806 -4.4 -5.6 -3.2 
Mucinous adenocarcinoma of ovary 0.813 0.657 -4.6 -7.2 -2.1 
Adenocarcinoma with variants of bladder 0.265 0.213 -4.7 -8.9 -0.5 
Undifferentiated carcinoma of stomach 0.189 0.123 -9.2 -13.9 -4.5 
 
 
 
Table 3. Age standardized 5-year relative survival (RS) in 1999-2001 and 2005-2007, and corresponding difference between the two periods, of rare cancers lying outside the 3-
standard-errors confidence bounds in Figure 2 
 
  
Cancer entity 
1999-2001 
5-year RS 
2005-2007 
5-year RS 
Difference 
99.8% Confidence 
interval 
lower upper 
Chronic myeloid leukemia 
37.2 57.9 20.7 17.4 24.1 
Infiltrating duct carcinoma of prostate 
67.5 79.8 12.3 6.4 18.2 
Soft tissue sarcoma of viscera 
34.7 43.7 9.0 3.6 14.4 
Kaposi's sarcoma 
75.4 84.2 8.8 1.4 16.2 
Diffuse B lymphoma 
46.9 55.2 8.4 6.5 10.2 
Follicular B lymphoma 
69.5 77.9 8.4 5.9 10.8 
GEP, Poorly differentiated endocrine carcinoma of pancreas and digestive system 
25.3 32.7 7.5 2.7 12.2 
Squamous cell carcinoma with variants of oropharynx 
37.5 44.5 7.1 5.0 9.2 
Soft tissue sarcoma of superficial trunk 
43.9 50.4 6.5 1.4 11.6 
Precursor B/T lymphoblastic leukemia/lymphoma (and Burkitt leukemia/lymphoma) 
54.3 60.8 6.4 3.8 9.1 
Plasmacytoma/Multiple Myeloma (and Heavy chain diseases) 
29.8 35.0 5.2 3.8 6.7 
Carcinomas of thyroid gland 
85.6 90.6 5.0 3.8 6.3 
Adenocarcinoma with variants of cervix uteri 
63.8 68.8 5.0 1.7 8.3 
GEP, Well differentiated not functing endocrine carcinoma of pancreas and digestive 
system  
67.7 72.6 4.9 1.5 8.4 
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Soft tissue sarcoma of limbs 
63.9 68.4 4.4 1.0 7.9 
Adenocarcinoma with variants of oesophagus 
9.9 13.8 3.9 2.6 5.1 
Squamous cell carcinoma with variants of oral cavity 
46.1 49.7 3.7 1.7 5.6 
Squamous cell carcinoma with variants of hypopharynx 
22.2 25.6 3.4 0.5 6.3 
Other myeloproliferative neoplasms 
70.8 74.0 3.2 0.6 5.9 
Squamous cell carcinoma with variants of cervix uteri 
65.1 68.1 3.0 1.6 4.5 
Large cell carcinoma of lung 
10.9 13.6 2.7 1.6 3.9 
Adenocarcinoma with variants of EBT 
16.2 18.7 2.6 0.2 5.0 
Squamous cell carcinoma with variants of oesophagus 
9.5 12.0 2.5 1.3 3.7 
Hepatocellular carcinoma of Liver and IBT 
11.0 13.0 2.0 0.5 3.5 
Other myelodysplastic syndrome 
33.8 30.2 -3.5 -6.3 -0.8 
 
 
 
Table 4. Annual number of cases, number of hospitals providing 75% of treatments (H75), mean annual number of treatments (treat) provided by H75 hospitals, by country and cancer 
group 
 
Country, population (millions) 
Group of cancer Belgium (10.5) Bulgaria (7.7) Finland (5.3) Ireland (4.2) Netherlands (16.3) Slovenia (2.0) Navarra (0.6) 
 
cases H75 treat cases H75 treat cases H75 treat cases H75 treat cases H75 treat cases H75 treat cases H75 treat 
Haed & Neck 
2,098 29 105.6 1,180 10 145.1 439 6 82.2 368 7 63.0 2,439 12 201.4 395 2 266.1 125 2 76.6 
Epithelial Ovary 
760 50 19.5 627 16 52.3 370 10 44.5 261 15 21.0 1,118 47 30.2 158 3 82.0 38 1 45.5 
Oesophagus 
689 31 29.3 77 14 5.2 163 8 21.6 289 9 37.1 1,422 31 42.0 49 2 32.9 24 2 15.7 
Central Nervous 
System 
623 20 48.4 412 13 41.7 57 4 19.1 229 3 106.3 912 14 84.0 97 2 78.7 47 2 32.0 
Soft Tissue Sarcoma 
500 35 16.6 372 21 18.4 165 7 25.6 157 17 10.6 802 33 26.4 81 2 47.4 32 2 17.4 
Thyroid 
576 34 14.2 220 12 20.4 286 12 22.8 98 11 9.6 418 31 17.1 109 1 260.3 43 2 36.8 
Testis 
244 40 8.4 180 19 12.4 101 9 14.3 144 12 15.6 609 42 18.4 93 3 48.8 10 3 4.4 
Biliary Tract 
214 44 4.9 183 23 6.5 147 13 11.3 122 14 7.7 582 38 12.2 47 3 13.2 43 2 19.7 
GEP 
287 46 5.6 30 21 1.3 148 13 9.3 61 20 2.7 355 44 6.9 22 3 6.8 10 3 2.9 
Liver 
250 22 11.0 107 12 7.6 165 11 12.8 68 12 4.6 236 36 5.2 29 2 14.4 49 3 14.5 
Urinary Tract 
292 48 6.7 67 17 4.1 48 12 3.9 24 10 2.3 419 46 7.7 30 3 8.9 19 3 8.2 
Mesothelioma 
184 25 8.7 34 10 3.7 64 9 6.8 25 11 2.0 481 43 9.8 21 1 22.3 9 2 4.6 
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Vagina 
172 35 5.8 120 9 14.0 70 5 14.8 40 9 4.7 296 14 21.8 42 2 21.9 8 2 4.7 
Bone Sarcoma 
81 10 10.2 55 13 4.6 28 3 9.6 30 7 5.2 195 5 43.3 15 2 10.4 3 2 2.4 
Anal Canal 
95 27 5.3 39 12 4.1 24 7 4.6 30 9 4.4 135 22 7.2 15 1 23.6 4 2 3.6 
Melanoma of uvea 
43 2 21.9 17 7 2.7 6 1 5.5 29 4 5.7 156 2 80.2 13 1 11.9 3 3 0.8 
Penis 
63 43 1.4 39 17 2.4 21 10 2.1 20 15 1.2 109 26 3.7 9 4 2.0 4 3 1.2 
Small Intestine 
62 37 1.9 15 13 1.1 26 13 2.1 27 20 1.3 120 38 2.6 5 4 1.3 2 2 1.0 
Neuroendocrine 
carcinoma of skin 
46 32 1.9 1 3 0.4 0   15 18 0.8 77 37 2.3 4 4 1.1 0   
Non epithelial Ovary 
20 19 1.3 43 17 3.2 8 9 1.1 8 15 0.6 32 24 1.4 4 3 1.7 1 3 0.3 
Endocrine carcinoma 
of thyroid 
31 22 1.4 10 9 1.2 8 8 1.2 5 10 0.5 32 13 2.7 5 1 10.3 1 1 1.7 
Thymus 
22 20 1.4 7 8 1.3 4 5 1.1 5 5 1.3 36 15 2.8 3 2 2.1 2 2 1.3 
Nephroblastoma 
18 4 7.4 6 3 2.8 8 3 4.7 7 1 13.4 30 4 16.9 3 1 4.8 0 1 0.3 
Melanoma of mucosa 
14 24 0.8 2 5 0.8 10 7 1.7 6 11 0.6 34 13 3.0 4 3 1.5 1 2 0.3 
Adrenal cortex 
13 14 1.1 13 10 1.3 6 7 0.9 5 11 0.4 25 15 1.5 3 2 1.4 1 2 0.4 
Embryonal CNS 
21 9 4.2 14 9 2.5 6 3 3.1 9 3 6.3 0    2 4.2 2 1 5.2 
Neuroblastoma 
15 4 5.7 8 5 1.7 1 1 2.1 7 2 5.4 12 4 6.2 1 2 1.3 1 1 1.8 
Retinoblastoma 
10 1 14.0 3 5 0.5 3 2 1.5 3 2 1.8 22 1 30.7 1 1 1.1 1 2 0.5 
Trachea 
10 18 0.9 5 4 1.1 4 5 0.9 2 4 0.4 11 11 1.1 3 1 3.8 1 1 0.5 
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Background 
Rare cancers here defined as those with an annual incidence rate less than 6/100,000 in Europe, 
 pose challenges for diagnosis, treatments, and clinical decision-making. Information on rare 
cancers is scant. We updated the estimates of the burden of rare cancers in Europe, their time 
trends in incidence and survival, and provide information on centralization of treatments in seven 
European countries. 
Methods 
We analysed data on more than two million rare cancer diagnoses, provided by 83 cancer 
registries, to estimate European incidence and survival in 2000-2007 and the corresponding time 
trends during 1995-2007.  Incidence rates were calculated as the number of new cases divided 
by the corresponding total person years in the population. Five-year relative survival (RS) was 
calculated by the Ederer-2 method. Seven registries (Belgium, Bulgaria, Finland, Ireland, 
Netherlands, Slovenia, and the Navarra region in Spain) provided additional data on hospitals of 
treatment for about 220,000 cases diagnosed in 2000-2007. Hospital volume was calculated as 
the number of treatments provided by each hospital rare cancer group sharing the same referral 
pattern.  
Findings 
Rare cancers accounted for 24% of all cancers diagnosed in EU28 during 2000-2007. The overall 
incidence rose yearly by 2.3%. RS  increased (overall 5.7%), from 1999-2001 to 2007-2009, and 
for the majority of rare cancers, with the largest increases for hematological tumors and 
sarcomas. The level of centralization of rare cancer treatment varied widely between cancers and 
between countries. The Netherlands and Slovenia had the highest treatment volumes. 
Interpretation 
The study profits from the largest pool of population-based registries to estimate incidence and 
survival of about 200 rare cancers. Incidence trends can be explained by changes in known risk 
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factors, improved diagnosis, and registration problems. Survival could be improved by early 
diagnosis, new treatments and better case management. There is ample room for improving the 
centralization of treatment in these seven European countries. 
The research was funded by the European Commission (Chafea) [Grant No. 2000111201]. 
 
Introduction 
The RARECARE project defined rare cancers as those with an annual incidence rate less than 
6/100,000 in Europe (EU), and showed that about one in five were rare types and slightly more 
than four million rare cancers were prevalent in the EU population [1]. Because of their low 
numbers, the almost 200 rare cancers listed by RARECARE pose challenges for diagnosis, 
treatments, and clinical decision-making. Clinical trials are rare too, and it is hard to build up new 
knowledge and expertise.  
There is a broad consensus that the diagnostic pathologic confirmation and primary treatment of 
rare cancers, in particular, should be centralized in reference centers and/or in collaborative 
networks, with multidisciplinary approaches [2] and very specific expertise. In addition, clinical 
and translational research calls for a high level of centralization and international collaboration. To 
what extent appropriate policies for rare cancer patients are implemented at the country level has 
seldom been studied.  As a consequence, information for policy makers and stakeholders is 
scarce for many of these tumors. 
The project Information Network on Rare Cancers (RARECAREnet) is designed to update 
epidemiological information on rare cancers in the EU [3], to provide indicators at the country 
level, time trends, and to study to what extent treatment is centralized in Europe.  
This paper provides up-to-date incidence and survival estimates based on data collected from 94 
population-based cancer registries (CRs), for 198 rare cancers diagnosed in 2000-2007 and for 
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12 major families of rare cancers. It also presents data on the levels of centralization for rare 
cancers in selected European countries.  
Material and Methods 
Patients 
The data were extracted from two databases. The first, the descriptive analysis database, is a 
subset of the EUROCARE-5 database [4]. It includes incidence and follow-up data provided by 
European population-based CRs regarding cancer patients diagnosed in the period  Jan 1,1978, 
to Dec 31, 2007.1978-2007. Vital status was updated to  Dec 31,  2008.the end of 2008. From the 
117 CRs participating in EUROCARE-5, we excluded specialized pediatric CRs, the Swedish and 
Turin CRs, because they did not participate in the RARECAREnet study, and the Danish CR, 
because it provided none of the details on morphology needed to define rare cancers. Details of 
the RARECAREnet database can be found in the report on the project website [5]. For the 
analysis of incidence we excluded 11 CRs specialized in specific anatomical sites to avoid 
incomplete coverage of some cancer entities affecting multiple sites such as neuroendocrine 
tumors. A total of 1,984,147 rare cancer diagnoses were considered for incidence estimates in 
2000-2007, collected by 83 CRs from 1,566 million person-years of observation. Data for 
incidence trends came from 42 CRs covering the period 1995-2007, and included 2,268,602 
cases, and 1,900 million person-years of observation. Survival estimates in 2000-2007 for all the 
rare cancers were based on a total of 1,994,346 diagnoses, observed by 94 CRs. Case identified 
only with death certificate (DCO) or casually discovered at autopsy were excluded from the 
analysis because they do not report time of survival. Cases lost to follow-up were considered as 
censored at the date of last contact.  Multiple primaries in a same patient were included. Death 
certificate only (DCO) and autopsy cases were excluded but data included multiple primaries in a 
single patient. Finally, survival trend analysis was based on 1,649,309 rare cancer diagnoses 
from 45 CRs providing uninterrupted data from at least Jan 1, 1995 to Dec 31, 2007.  
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1995 to 2007.  
The second database was used for the study of hospitals of treatment and hospital volume. It comes 
from seven European CRs: the national CRs of Belgium, Bulgaria, Finland, Ireland, Netherlands, 
Slovenia, and the regional CR of Navarra (Spain). This last, although regional, was added in 
consideration of the regional organization of the Spanish health care system. These CRs were selected 
to reflect the variability of incidence and survival in Europe [1,5], and because they could provide 
detailed data for all 198 rare cancers. Variables included: sex, dates of birth and diagnosis, from the 
International Classification of Disease for Oncology version 3 ICDO-3 topography and morphology 
codes from the International Classification of Disease for Oncology version 3 (ICDO-3), grading, 
pathological and clinical TNM, simplified stage (localized, regional extension, metastatic), treatment 
(surgery, radiotherapy, systemic, other or none), vital status, date of closure of follow-up or death, 
hospital of diagnosis and hospital of treatment.  DCO and autopsy cases (1.3% overall, with a 
maximum of 8.6% in Bulgaria) were not included. The hospital of diagnosis was defined as the hospital 
where the pathology examination was done or requested. The hospital of treatment(s) was defined as 
the hospital where a specific treatment (e.g. surgery) or the first course of systemic therapy (e.g. 
chemotherapy) was given. Up to five different types of treatment within one year from the date of 
diagnosis were considered as a primary treatment. Vital status was further updated, with respect to the 
descriptive analysis database, to Dec 31, 2012.to the end of 2012.  
We received data on about 348,000 rare cancers diagnosed in the period 2000-2007. However, 
national data from Belgium were limited to the period of diagnosis 2004-2007, and those from Navarra 
to 2000-2005. Cases diagnosed in Bulgaria and the Netherlands during 2000-2004 were removed on 
account of incomplete national coverage of hospital information. A total of 223,081 rare cancer cases 
were included in the hospital volume study database. Unspecific morphologies (8000, 8001, 8010, 
8800, 9800, 9590) were found in 2.1% of cases, with the highest proportion (4.1%) in Finland. 
Seventeen per cent of cases (37,959/223,081) was removed, because for them the information of 
hospital was missing. 
 
Methods 
Rationale of the definition of rare cancer entities and their classification in terms of ICD-O codes 
are reported elsewhere [1,2,5]. Classification was structured in way to avoid any overlapping 
among rare entities. For example, GEP NET and GIST tumours were under the families of NET 
and sarcomas, and not also in digestive rare cancers. 
Incidence rates were estimated as the number of new cases arising in 2000-2007 divided by the 
corresponding total person years (male + female) in the general population. The European 
standard population was used for direct age standardization. New cases in 2013 in EU28 were 
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calculated by multiplying age- and sex-specific incidence rates in 2000-2007 by the 
corresponding European population classified in five-year age classes on 1 January 2013. 
Incidence variation over time was estimated restricting the analysis to 1,480,424 cases diagnosed 
in the two sub-periods 1999-2002 and 2003-07, and was presented in a funnel plot where each 
dot represents a single rare cancer, the y-axis displays the estimated difference in terms of 
annual percent change (APC) of age-adjusted incidence, and the x-axis the corresponding 
precision in terms of the inverse of its standard error. APC was calculated as the ratio between 
incidence rates for the two sub-periods elevated to 1/4.5, the inverse of their mean time distance. 
Three-standard-deviation confidence intervals for estimated zero changes [6] are represented by 
two symmetrical lines progressively approaching the x-axis with increasing x values. Dots lying 
above or below the area between them correspond respectively to tumors with 99.8% significantly 
higher or lower incidence rates. 
Five-year relative survival (RS) was estimated as the ratio of observed to expected survival in the 
general population, matched by age, sex, calendar year, and geographical area, and calculated 
by the Ederer-2 method [7].  RS time trends were estimated by the period approach considering 
three follow-up periods: 1999-2001 (cohorts diagnosed  in Jan 1,1995 to Dec 31, 2001in 1995-
2001), 2002-04 (cohorts diagnosed in  Jan 1,1998 to Dec 31, 20041998-2004), and 2005-07 
(cohorts diagnosed in  Jan 1, 2001 to Dec 31, 20072001-07). RS changes were presented as a 
funnel plot, similarly to incidence changes, but using the difference between five-year RS in the 
last and first of these periods on the y-axis. 
The volume (number) of treatments provided by each hospital was calculated for major cancer groups, 
defined by aggregating all the solid rare cancers into 38 groups sharing the same referral pattern (see 
Figure 3). For example, all the 17 head and neck tumors, identified [1] as clinically distinct rare entities, 
 head and neck tumors are usually referred to head and neck specialized services, and were 
considered as a single group. Hematological rare tumors, not always requiring hospitalization, 
were not considered in the volume analysis.  Hospital volume for each of the 38 groups was then 
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computed as the annual number of any treatment delivered by the hospital, for all the cancers in 
that group. Repeated admissions to the same hospital for the same cancer and the same 
treatment type (i.e. surgery, radiotherapy or systemic therapy) were considered as a single 
admission and counted as one treatment in the analyses. Instead, repeated admissions for 
several treatment types (such as radiotherapy and subsequent surgery) given to a patient in the 
same hospital were all counted as treatments. Untreated patients were assigned to the hospital of 
diagnosis. The total number of treatments provided by each hospital for a given group of rare 
cancers was then divided by the number of years of observation to provide its mean annual 
hospital volume.  
Finally, for each patient we calculated the mean annual volume of the hospital(s) where they were 
treated, so obtaining a patient-specific measure with a much less skewed distribution with respect to 
the hospital-specific volume.. Averaging this measure over all the patients diagnosed with a given 
group of rare cancers in a certain country gives a cancer- and country-specific measure of the level of 
expertise that patients can expect for the treatment of their tumor. We called it the mean admission 
volume (MAV) indicator. 
Role of the funding source 
The funders had no role in study design, collection, analysis or interpretation of data, or writing of the 
report. The corresponding author had full access to all the data and had final responsibility for the 
decision to submit for publication. 
 
Results 
Burden of rare cancers in Europe 
Table 1 provides incidence and survival estimates for each of the 198 rare cancers, for 63 groups 
of rare cancers (capital letters), for the 12 wider families in which rare cancers are hierarchically 
grouped, and for six common cancer groups.  Hematological malignancies, rare cancers of 
female genital organs and of the digestive tract, and head and neck cancers were families with 
the highest overall incidence rates (from 15 to 28/100,000/year). Thoracic cancers, male genital 
and urological, endocrine organs, central nervous system (CNS) tumors and sarcomas had 
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overall incidence rates from 5 to 8/100,000. Rare skin cancers and non-cutaneous melanoma, 
and embryonal cancers were the families with the lowest rates (1.22 and 0.34 per 100,000). 
Overall, rare cancers accounted for 24% of all cancers diagnosed in EU28 during 2000-2007; by 
far the majority were solid cancers (76%). For sex-specific rare cancers, we also provide in 
supplementary table (see appendix p xxx41) sex specific incidence rates. 
Five-year RS of all rare cancers together was 49%, compared to 63% for all common cancers.  
Rare cancers also had lower survival within the families of digestive cancers (15% vs. 41%), 
female genital cancers (58% vs. 82%), male genital and urologic cancers (74% vs. 76%), skin 
cancers (70% vs. 96%) and hematological tumors (51% vs. 61%). The only exception was the 
group of thoracic cancers (13% vs. 10%), where common cancers included squamous cell 
carcinoma of the lung - with a very bad prognosis (6% after five years).  Families including only 
rare cancers had five-year RS ranging from high, as for embryonal and endocrine organ tumors 
(79% and 88%), to intermediate, for sarcomas (60%), neuroendocrine (54%) and head & neck 
tumors (52%), and low for CNS tumors (21%).  
Time trends of incidence and survival for rare cancers are shown in Figures 1 and 2. Cancers 
whose incidence variation fell outside the confidence interval shown in Figure 1 are listed in Table 
2, with the age-standardized incidence estimates for 1999-2002 and 2003-2007, the 
corresponding APC and three-standard-error confidence intervals. Rare cancer dots in the plot 
seem to be distributed fairly symmetrically around the zero-change line, indicating no major 
systematic shifts in incidence. Overall there was a slight increase: the average APC for all the 
entities was +2.3% per year.  There was a significant increase in incidence (99.8%) for 16 rare 
cancers, and a significant decrease for ten. Trends of rare cancers did not substantially differ 
from those of common cancers (data not shown), whose average annual change was +0.9%. 
Only prostate and skin cancers had an APC greater than 2%, while only epithelial cancers of the 
stomach decreased more than 2%.  
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Survival increased from 1999-2001 to 2005-2007 for the majority of rare cancers. The cloud of 
points in Figure 2 is skewed upward from the zero line, corresponding to a mean increase in 
survival, averaged over all the entities, of about 5.7 percent points. Twenty-four rare cancers 
presented significant survival increases (Table 3), while only one (other myelodysplastic 
syndromes) had a slight but significant decrease. Rare cancers with the largest survival increases 
were mainly hematological: chronic myeloid leukemia, diffuse B cell lymphoma, follicular 
lymphoma, precursor B/T lymphoblastic leukemia/lymphoma, and multiple myeloma. Well 
represented among the top tumors with increasing survival were sarcomas, specifically of the 
viscera, trunk, and Kaposi sarcoma. Survival increases higher than five percent points were also 
observed for infiltrating ductal carcinoma of the prostate (12 percent points), poorly differentiated 
endocrine carcinoma of the digestive system (7.5 percent points), and squamous cell carcinoma 
of the oropharynx (7.1 percent points). There were no major improvements for rare cancers of the 
colon, rectum, breast and kidney, differently from the corresponding groups of common cancers 
[8].  
 
Where are rare cancers treated?  
Figure 3 illustrates the extent of centralization of rare cancer treatment, presenting MAV, overall and by 
country, for 38 cancer groups ranked by decreasing incidence. Logarithmic scale is here used for the x-
axis to made the graph readable despite the huge MAV variability (from 82 to 0.2 per year) across the 
considered cancers.  A supplementary Table (see appendix p xxx43) Supplementary Table 1 gives the 
numbers for the graphs. Pooled MAV (Figure 3a) ranged from a maximum of 83 treatments per year for 
head and neck tumors to fewer than 0.5 per year for choriocarcinoma of the placenta, some embryonal 
and endocrine tumors. The higher the incidence, the larger the MAV of treating hospitals. The 
relationship between cancer incidence and MAV in the pool of countries was very strong (Pearson 
coefficient 0.88), though with several outliers. This was the case for epithelial tumors of the ovary, 
which had a higher incidence but a lower MAV than CNS tumors, whose patients seemed therefore to 
be more centralized than ovarian cancer patients (35 vs. 20 cases treated per year). Similarly, soft 
tissue sarcomas had a five times higher incidence, but received less centralized treatment than bone 
sarcomas. Treatment  for for thyroid cancers, uveal melanoma and several embryonal tumors appeared 
to be fairly concentrated in few hospitals with relatively high volumes. In contrast, tumors of the urinary 
tract, gastro-entero-pancreatic neuroendocrine tumors (GEP-NET), small intestine, non-epithelial ovary 
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cancers, and NET of skin were treated in centers with an even lower MAV than would be expected 
because of their very low occurrence.  
With some exceptions, country-specific patterns of MAV reflected the overall picture. Differently from 
what found in the other countries, the management of epithelial ovarian cancers was highly centralised 
In Bulgaria and Slovenia.Centralization of epithelial ovarian cancers was not low in Bulgaria and 
Slovenia. CNS patients were treated in highly centralized structures in all countries except Finland and 
Navarra. Treatment for uveal melanoma and retinoblastoma was not centralized in Bulgaria and, again, 
in Navarra. Slovenia and the Netherlands had the highest centralization patterns, while MAV for the 
majority of cancers was very low in Navarra. 
Table 4 presents, for each country and 29 rare cancers, the annual number of cases diagnosed, 
the number of top-volume hospitals treating at least 75% of national cases, and the average 
annual numbers of treatments provided. Taking for example head and neck cancers, 3/4 of 
patients were centralized in two top hospitals in Slovenia (2 million population, 266 treatments per 
hospital per year), and 12 top hospitals in the Netherlands (17 million population, 201 treatments 
per hospital per year). The level of centralization was lower in the other countries, resulting in a 
caseload of 145 in the ten Bulgarian top hospitals, 106 in the 29 Belgian hospitals, and 
respectively 83, 77, and 63 in Finland, Navarra and Ireland. The Netherlands and Slovenia had 
the highest treatment volumes out of the 29 considered, with 12 rare cancers each. 
 
Discussion 
 
Rare cancers make up one quarter of all malignancies. They are a very heterogeneous group of 
almost 200 cancers, mostly solid, constituting from 2% of all skin cancers up to 32% of all female 
genital cancers. We confirmed the lower five-year survival for rare than common cancers (49% 
vs. 63%), and for all cancer families except  thoracic cancers. The disadvantage persisted even 
after excluding common cancers with good prognosis, of prostate, breast and skin. Several 
factors help explain these differences: the biology of the diseases, adequacies of diagnosis and 
treatment, lack of effective therapies, or lack of evidence-based treatment guidelines. 
14 
 
A novelty of this study is the analysis of incidence and survival trends. Overall, incidence rose by 
2.3% a year from 1999 up to 2007. The increase was substantial for several rare cancers (Figure 
1). Some of the increase can probably be attributed to improvement in pathological diagnosis,  
new entity codes in the ICD-O-3 and to the time needed to adapt the coding procedures. This is 
the case of GIST, large cell carcinoma of the lung, neuroendocrine tumours and many 
hematological codes [9-11]. For other rare cancers, increases in incidence may be due to better 
pathological diagnosis, like for the neuroendocrine tumors. For thyroid carcinoma several authors 
have suggested an increase in over-diagnosis [12]. However, increased exposure to risk factors 
may explain higher incidence rates for oropharynx and anal canal squamous cell cancers due to 
human papillomavirus (HPV) [13,14] and for adenocarcinoma of the esophagus, perhaps due to 
increasing obesity or gastro-esophageal reflux [15]. The lower squamous cell carcinoma cervix 
incidence might reflect organised cervical screening programs. The drop in incidence for some of 
the rare cancers was due to the still falling prevalence of smoking [16]. 
RS improved by about 3% overall, slightly less than for common cancers (5.5%, data not shown), 
suggesting that investments were more focused on these latter.  Also, over-diagnosis is expected 
to affect more common than rare cancers. Success was greatest for chronic myeloid leukemia 
(CML) with a five-year gain in survival of 21% across the study years, largely explained by the 
widespread use of new and more effective treatments, such as targeted treatments and more 
effective stem-cell transplantation [17]. For many other hematological cancers, new (targeted) 
drugs, combination with radiotherapy and again improvement in transplantation are responsible 
for the impact on prognosis [18]. Survival also improved for some groups of sarcoma (viscera, 
trunk and limbs) for which multidisciplinary approaches and centralization of treatments may take 
the credit. This may also be true for neuroendocrine tumors [19], biliary tract, liver [20] and 
esophageal cancers [15], for which there are now more specific and effective 
treatments/protocols. For esophageal cancers, earlier detection through Barrett's esophagus 
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surveillance practices might also contribute. For oropharyngeal cancers, the larger proportion of 
less aggressive tumors attributed to HPV may have influenced the survival gain [21]. For 
carcinoma of the thyroid and infiltrating ductal carcinoma of the prostate, early diagnosis should 
be the major factor. This would also have contributed to a rise in the proportion of cases that are 
clinically irrelevant, though this is hard to estimate [12, 22]. As found for incidence,  
Like for incidence, some of the apparent survival gains may be due to classification changes [9], 
such as for large cell carcinomas of the lung.  
Myeloproliferative neoplasms and myelodysplastic syndromes were not considered cancers until 
the WHO classification was changed in 2001, and their registration started even later [9]. More in 
general, the increases in incidence of some rare cancers could be due to more specific diagnosis 
and coding by registry.  
The hospital volume analysis represents the first attempt to systematically study the place of 
treatment of rare cancers from population-based CR data. Many potentially relevant indications 
can be drawn from this seldom used source of information. However, several important limitations 
must be recognized. Seven CRs cannot be considered as statistically representative of the whole 
European population. Bulgaria, Finland and Navarra only provided information on, at most, three 
treatments: the first surgical, systemic and radiotherapy treatments. However, we estimated from 
the data of the other CRs that this problem only regard  about 1% of all patients.  
The mean admission volume estimates, based on individual patient data and blind administrative 
coding of hospitals, will depend on how cancer services were organized and coded. We cannot 
know if, for some rare cancers and in some countries, hospitals were linked in organized 
networks during the study period, thus overcoming an apparent dispersion of treating structures. 
For example, patients with localised sarcomas or head and neck cancers were more frequently 
treated by small and/or peripheral hospitals [23]. If several hospitals provided different services 
but acted co-operatively as a single specialist center, their estimated volume will depend on 
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whether they were identified as a single or separate units.  Our data do not allow identifying in 
detail specific protocols used in the considered hospitals. Hospital volume can be therefore 
considered as an only partial quality indicator, mainly pointing to level of experience in protocol 
application and general management of  rare cancer patients.  Not all the seven CRs participating 
in this part of the study were able to provide the admission dates, so we could not analyse the 
treatment delay and timings. Bulgaria, Finland and Navarra only provided information on, at most, 
three treatments: the first surgical, systemic and radiotherapy treatments. However, our definition 
of hospital admission volume was based on one admission per treatment type per hospital, so we 
only lose duplicated surgical or systemic treatments done in different hospitals. We estimated 
from the data of the other CRs that this only happens for about 1% of all patients.  
The use of individual patient data only provides a partial picture of cancer care organization in a 
country. We cannot exclude that, for some rare cancers and in some countries, hospitals were 
linked in organized networks during the study period, thus overcoming an apparent dispersion of 
treating structures. For example, patients with localised sarcomas or head and neck cancers 
were more frequently treated by small and/or peripheral hospitals [23]. In some countries several 
hospitals provide different services but act co-operatively as a single specialist center. Finally, 
seven CRs cannot be considered as statistically representative of the whole European 
population.  
There are several suggestions that centralization of care improves outcome for rare cancers [24]. 
This is particularly true when optimal treatment requires complex surgery or high-technology 
radiotherapy equipment. It is beyond the scope of this paper to address the volume-survival 
relationship. Diagnosis and treatment in reference centers are expected to be more accurate 
because they benefit from large numbers of cases, which are often discussed in a 
multidisciplinary setting involving expert professionals. Often centralized sites are connected to 
research centers participating in international debates and research. Disadvantages of 
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centralization are the need for patients to move and the risk of a longer waiting list, with 
consequent discomfort and possible negative effects on outcome [25].  
Sometimes, centralisation was only moderately perceived by oncologists as a solution to be 
endorsed for rare cancer patients.[26]  
National cancer plans should specifically address the needs of rare cancer patients from 
diagnosis to treatment and palliative care, regulate their referral to centers of expertise while 
avoiding bottleneck effects in the designated hospitals, and include periodic evaluation of 
outcomes. For very rare diseases and small countries, international networks could be the best 
option. 
For many of the solid rare cancers, centralization did not seem to have been completely achieved 
during the study period. However, most cases had been diagnosed more than ten years ago 
when centralization for cancer patients did not necessarily have much priority. Centralization 
seemed to be more widely implemented for rare cancers requiring highly specific technologies 
(particularly radiotherapy and nuclear medicine) and for those with long-established evidence-
based guidelines for diagnosis and treatment. This was the case for many pediatric tumors, uveal 
melanoma, anal canal cancers, adrenal cortex cancers and, for specific surgical expertise, in 
CNS cancers and bone sarcomas. Our data also suggest that centralization is implemented less 
for cancers affecting the elderly. From our data, 26% of rare cancers affect patients aged over 75 
(not shown), for whom systemic therapy is often preferred to surgery more than for younger 
cases.  
The degrees of centralization varied across Europe, and to a large extent were affected by the 
population size. In countries with a small population it is easier to concentrate patients in a single 
or few hospitals. High admission volumes are more likely to be achieved in reference centers in 
larger-population countries.  
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The results of this part of the study were discussed in the participating countries at dedicated 
meetings attended by public health planners, oncologists, surgeons, representatives of Ministries 
of Health and patient associations. While the general pattern of dispersion was recognised, 
almost all the countries were working at different levels to implement centralization and/or 
network-based organizations for treatment, while still following country-specific priorities [2627].  
Belgium and the Netherlands are the two largest countries in the study. In Belgium, where all 
cancer patients can be treated in any hospital with an oncology care program, the level of 
centralization was low. The need was recognized to improve collaboration, centralization of care 
and knowledge sharing. A plan is now under way for the development of hospital networks 
between centers of expertise for rare cancers and other oncology care services/programs. 
Centralization was already ongoing in the Netherlands, mostly for surgical treatment. This was 
reflected in the high admission volumes in this country for many rare cancers (see Table 
S1appendix p xxx41).  
In Bulgaria rare cancer patients were operated in all hospitals with surgical departments, while 
radiotherapy was concentrated in 17 centers and systemic therapy in 14 oncological hospitals. A 
major issue remains the quality of diagnosis, mainly due to inadequate facilities and abilities to 
diagnose many complex rare cancers. The definition of national and international pathways for 
second opinions from expert pathologists was also deemed important. With this in mind, the 
European Reference Networks should offer a good opportunity to improve pathologist training 
through dedicated training schemes and fellowships across Europe. Cancer registration remains 
vital for monitoring progress in rare cancer diagnosis and treatment for these patients. 
In Finland, more than 60% of rare cancer patients were treated in five university hospitals. 
Centralization in single national structures was only observed for uveal melanoma and 
retinoblastoma. Further centralization for other rare cancers is impeded by the spread of the 
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population over large areas and by administrative constraints on regional health authorities for 
referring cancer patients to the closest university hospital. 
Irish public health authorities, during the period covered by the study, identified, a few centers  to 
treat rare or particularly complex cancers. However, patients were not always correctly referred to 
them. This highlights the need for strong political commitment to ensure centralization, to make 
sure all rare cancer patients receive the highest quality of care.  
Cancer care was highly centralized in Slovenia. In addition, the major hospitals were organized 
on a task-specific basis: radiotherapy was only provided by the National Cancer Center, while 
surgical treatment was more often done in two other major hospitals. Reducing delays in 
diagnosis and treatment was recognized in Slovenia as one of the major challenges in order to 
improve rare cancer outcomes. 
Navarra is a relatively small region of Spain, a country with a highly regionalized health 
organisation. No hospital with national recruitment for rare cancers was operating in Navarra, and 
98% of resident rare cancer patients were treated locally, the majority in the two largest regional 
hospitals. However, the admission volumes of Navarra hospitals are much lower than in all the 
other participating countries, even considering some underestimation due to unregistered patients 
coming from outside the region. This suggests some disadvantages in organizing rare cancer 
treatment on a regional/local basis. 
To conclude, this is the largest study that estimates the burden of rare cancer for Europe, including 
trends in incidence and survival rates. It also provides indicators of rare cancer treatment management. 
In seven European countries we observed - with few exceptions - a low level of centralization of 
treatment for rare cancers. We recognise the importance of population-based cancer registries in 
descriptive studies like this, to ensure surveillance. However, the quality of the data needs to be 
improved when morphology, hospital and treatment definitions are considered. To this aim, the use of 
specific data quality indicators, the planning of periodic sample-based quality studies and, above all, a 
wider use of these variables in population based studies, with related sensitivity analysis, can be 
suggested. Furthermore, the international classification for cancer have to rapidly include the new 
entities based on molecular and genomic categorization. The latter is a necessary condition for 
updating a new rare cancers list. 
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The European network of cancer registries (ENCR) should work to boost these quality 
improvements and make wider use of the data on rare cancers. The Joint Action of Rare Cancers 
[2728] and the European Network for Rare Diseases will profit from these data, which are also 
useful for national and European policies to organize care for rare cancer patients better. The 
RARECAREnet project website includes a search tool with data for all the countries that 
contributed data [3]. 
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Table 1. Estimates of incidence and survival  for rare and common cancers, together with expected number of new cases 
 
 
 
         
 
Family 
Cancer entity Crude 
Incidence 
Rate per 
100,000 per 
year 
95% 
Confidence 
Interval                      
lower     upper 
Number of 
observed 
cases in 83 
CRs in 
2000-2007 
Estimated 
new cases 
at 2013 in 
EU (28) 
Five-year 
relative 
survival 
(%) 
95% 
Confidence 
Interval                      
lower     upper 
Number of 
observed 
cases in 94 
CRs in 
2000-2007 
 
RARE CANCERS      
    
 
Head and neck 
cancers 
  18.82 16.76 16.89 263,565 84,989 52.1 51.8 52.3 254,563 
 
  EPITHELIAL TUMOURS OF NASAL CAVITY AND SINUSES 
0.45 0.44 0.46 7,046 2,282 47.3 45.8 48.8 6,867 
 
  Squamous cell carcinoma with variants of nasal cavity and sinuses 0.35 0.34 0.36 5,465 1,770 49.5 47.8 51.2 5,444 
 
  Lymphoepithelial carcinoma of nasal cavity and sinuses 
0.00 0.00 0.00 31 10 70.8 50.7 99.0 31 
 
  Undifferentiated carcinoma of nasal cavity and sinuses 
0.02 0.02 0.02 286 93 30.5 24.3 38.2 283 
 
  Intestinal type adenocarcinoma of nasal cavity and sinuses 0.00 0.00 0.00 42 14 65.0 48.9 86.4 42 
 
  EPITHELIAL TUMOURS OF NASOPHARYNX 
0.47 0.46 0.49 7,439 2,580 48.9 47.5 50.2 7,276 
 
  Squamous cell carcinoma with variants of nasopharynx 
0.36 0.35 0.37 5,613 1,941 48.5 47.0 50.1 5,589 
 
  Papillary adenocarcinoma of nasopharynx 0.00 0.00 0.00 17 6 58.7 36.2 95.3 17 
 
  
EPITHELIAL TUMOURS OF MAJOR SALIVARY GLANDS 
AND SALIVARY-GLAND TYPE TUMOURS 
1.39 1.37 1.41 21,794 7,059 62.8 62.0 63.7 21,364 
 
  Epithelial tumours of major salivary glands 
0.96 0.95 0.98 15,053 4,876 60.8 59.8 61.8 14,703 
 
  Salivary gland type tumours of head and neck 0.43 0.42 0.44 6,741 2,183 67.1 65.7 68.6 6,683 
 
  EPITHELIAL TUMOURS OF HYPOPHARYNX AND LARYNX 
6.33 6.29 6.37 99,176 31,545 52.0 51.6 52.4 96,793 
 
  Squamous cell carcinoma with variants of hypopharynx 
1.27 1.25 1.28 19,828 6,422 25.1 24.4 25.9 19,878 
 
  Squamous cell carcinoma with variants of larynx 4.61 4.58 4.64 72,210 23,389 60.5 60.1 61.0 71,928 
 
  EPITHELIAL TUMOURS OF OROPHARYNX 
3.32 3.29 3.35 52,017 16,848 40.9 40.4 41.4 50,843 
 
  Squamous cell carcinoma with variants of oropharynx 
3.12 3.09 3.14 48,812 15,810 41.3 40.8 41.8 48,401 
 
  EPITHELIAL TUMOURS OF ORAL CAVITY AND LIP 4.78 4.75 4.81 74,890 24,257 56.7 56.2 57.1 73,101 
 
  Squamous cell carcinoma with variants of oral cavity 
3.51 3.48 3.54 54,931 17,792 48.0 47.5 48.6 54,229 
 
  Squamous cell carcinoma with variants of lip 
1.02 1.00 1.04 15,984 5,177 89.5 88.5 90.5 15,899 
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  EPITHELIAL TUMOURS OF EYE AND ADNEXA 
0.04 0.04 0.05 679 247 80.6 75.9 85.6 673 
 
  Squamous cell carcinoma with variants of eye and adnexa 
0.03 0.02 0.03 421 136 88.9 83.0 95.2 422 
 
  Adenocarcinoma with variants of eye and adnexa 
0.01 0.01 0.01 134 43 58.7 49.1 70.1 134 
 
  EPITHELIAL TUMOURS OF MIDDLE EAR 
0.03 0.03 0.04 524 170 44.1 38.5 49.6 488 
 
  Squamous cell carcinoma with variants middle ear 
0.02 0.02 0.03 377 122 37.6 31.8 44.4 370 
 
  Adenocarcinoma with variants of middle ear 
0.00 0.00 0.00 50 16 83.8 70.5 99.5 50 
 
Digestive rare 
cancers 
  21.94 21.86 22.01 343635 112,351 15.3 15.2 15.5 321,375 
 
  EPITHELIAL TUMOURS OF OESOPHAGUS 
7.81 7.77 7.85 122,344 40068 11.98 11.8 12.2 119,522 
 
  Squamous cell carcinoma with variants of oesophagus 
3.36 3.33 3.39 52,597 17,036 11.7 11.3 12.0 53,225 
 
  Adenocarcinoma with variants of oesophagus 
3.26 3.24 3.29 51,138 16,564 13.9 13.5 14.2 51,250 
 
  Salivary gland type tumours of oesophagus 
0.00 0.00 0.01 63 20 13.7 6.4 29.0 64 
 
  Undifferentiated carcinoma of oesophagus 
0.04 0.04 0.05 695 225 6.8 4.9 9.4 712 
 
  RARE EPITHELIAL TUMOURS OF STOMACH 
0.33 0.32 0.34 5,146 1,886 15.9 14.7 17.1 5,157 
 
  Squamous cell carcinoma with variants of stomach 
0.12 0.11 0.12 1,807 585 17.5 15.6 19.7 1,800 
 
  Salivary gland-type tumours of stomach 
0.00 0.00 0.00 39 13 25.1 12.7 49.9 40 
 
  Undifferentiated carcinoma of stomach 
0.21 0.20 0.22 3,300 1,069 14.9 13.5 16.4 3,317 
 
  EPITHELIAL TUMOURS OF SMALL INTESTINE 
0.77 0.76 0.79 12,132 3,930 27.3 26.3 28.3 11,544 
 
  Adenocarcinoma with variants of small intestine 
0.59 0.58 0.60 9,219 2,986 27.9 26.8 29.0 9,193 
 
  Squamous cell carcinoma with variants of small intestine 
0.01 0.01 0.01 133 43 34.8 26.8 45.3 133 
 
  RARE EPITHELIAL TUMOUR OF COLON 
0.13 0.13 0.14 2,074 737 54.8 52.0 57.7 2,075 
 
  Squamous cell carcinoma with variants of colon 
0.03 0.02 0.03 400 130 37.1 31.8 43.4 395 
 
  
Fibromixoma and low grade mucinous adenocarcinoma of the 
appendix 
0.11 0.10 0.11 1,674 542 58.8 55.7 62.1 1,680 
 
  RARE EPITHELIAL TUMOURS OF RECTUM 
0.11 0.11 0.12 1,764 635 47.2 44.4 50.2 1,777 
 
  Squamous cell carcinoma with variants of rectum 
0.11 0.11 0.12 1,764 571 47.2 44.4 50.2 1,777 
 
  EPITHELIAL TUMOURS OF ANAL CANAL 
1.16 1.14 1.18 18,155 5,880 56.5 55.5 57.4 18,020 
 
  Squamous cell carcinoma with variants of anal canal 
0.81 0.80 0.82 12,691 4,111 63.0 61.9 64.1 12,847 
 
  Adenocarcinoma with variants of anal canal 
0.25 0.25 0.26 3,970 1,286 41.9 39.9 43.9 3,945 
 
  Paget s disease of anal canal 
0.00 0.00 0.00 21 7 62.9 38.0 104.0 21 
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  RARE EPITHELIAL TUMOURS OF PANCREAS 
0.07 0.07 0.08 1,159 414 20.2 17.4 23.3 1,116 
 
  Squamous cell carcinoma with variants of  pancreas 
0.02 0.02 0.03 361 117 5.9 3.6 9.6 347 
 
  Acinar cell carcinoma of pancreas 
0.03 0.03 0.03 449 145 19.0 14.8 24.3 427 
 
  Mucinous cystadenocarcinoma of pancreas 
0.01 0.01 0.01 109 35 35.9 26.3 49.0 106 
 
  Intraductal papillary mucinous carcinoma invasive of pancreas 
0.01 0.01 0.01 173 56 31.8 23.6 42.9 171 
 
  Solid pseudopapillary carcinoma of pancreas 
0.00 0.00 0.00 44 14 67.7 52.8 86.8 42 
 
  Serous cystadenocarcinoma of pancreas 
0.00 0.00 0.00 4 1 NE NE NE 4 
 
  Carcinoma with osteoclast-like giant cells of  pancreas 
0.00 0.00 0.00 19 6 NE NE NE 19 
 
  
EPITHELIAL TUMOURS OF LIVER AND INTRAEPATIC 
BILE TRACT (IBT) 
7.10 7.06 7.14 111,271 36,261 10.1 9.9 10.3 98,765 
 
  Hepatocellular carcinoma of Liver and IBT 
3.22 3.19 3.25 50,461 16,344 14.0 13.7 14.4 46,896 
 
  Hepatocellular carcinoma, fibrolamellar of liver and IBT 
0.02 0.02 0.03 387 125 28.1 23.3 33.8 390 
 
  Cholangiocarcinoma of IBT 
0.97 0.95 0.99 15,201 4,924 6.0 5.6 6.6 13,845 
 
  Adenocarcinoma with variants of liver and IBT 
0.41 0.40 0.42 6,457 2,091 6.6 5.9 7.4 6,311 
 
  Undifferentiated carcinoma of liver and IBT 
0.02 0.01 0.02 240 78 2.7 1.2 6.4 219 
 
  Squamous cell carcinoma with variants of liver and IBT 
0.01 0.01 0.01 147 48 14.6 9.1 23.4 143 
 
  Bile duct cystadenocarcinoma of IBT 
0.00 0.00 0.00 38 12 23.6 11.5 48.5 34 
 
  
EPITHELIAL TUMOURS OF GALLBLADDER AND 
EXTRAHEPATIC BILIARY TRACT (EBT) 
4.44 4.41 4.48 69,590 22,540 13.6 13.2 13.9 63,889 
 
  Adenocarcinoma with variants of gallbladder 
1.35 1.33 1.36 21,085 6,830 14.5 14.0 15.1 20,338 
 
  Adenocarcinoma with variants of EBT 
1.44 1.42 1.46 22,510 7,291 19.2 18.6 19.8 22,234 
 
  Squamous cell carcinoma of gallbladder and EBT 
0.03 0.03 0.03 496 161 8.8 6.3 12.3 476 
 
Thoracic rare 
cancers 
  6.80 6.76 6.84 106573 37,277 13.4 13.1 13.6 104,670 
 
  EPITHELIAL TUMOUR OF TRACHEA 
0.11 0.11 0.12 1,771 574 18.0 16.0 20.3 1,697 
 
  Squamous cell carcinoma with variants of trachea 
0.06 0.06 0.07 1,017 329 12.2 10.0 14.9 1,008 
 
  Adenocarcinoma with variants of trachea 
0.01 0.01 0.01 164 53 15.7 10.3 24.0 158 
 
  Salivary gland type tumours of trachea 
0.01 0.01 0.01 175 57 70.1 62.0 79.2 174 
 
  RARE EPITHELIAL TUMOUR OF LUNG 
4.37 4.34 4.40 68,452 24,930 14.9 14.6 15.2 67,936 
 
  Adenosquamous carcinoma of lung 
0.29 0.29 0.30 4,607 1,492 21.9 20.5 23.4 4,566 
 
  Large cell carcinoma of lung 
3.81 3.78 3.84 59,714 19,342 13.9 13.5 14.2 59,332 
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  Salivary gland type tumours of lung 
0.06 0.05 0.06 879 285 40.4 36.8 44.4 866 
 
  Sarcomatoid carcinoma of lung 
0.21 0.20 0.22 3,255 1,054 17.5 16.0 19.2 3,183 
 
  EPITHELIAL TUMOURS OF THYMUS 
0.18 0.17 0.19 2,795 905 64.3 62.1 66.6 2,729 
 
  Malignant thymoma 
0.14 0.14 0.15 2,268 735 69.3 67.0 71.8 2,248 
 
  Squamous cell carcinoma of thymus 
0.01 0.01 0.01 114 37 40.4 30.4 53.7 112 
 
  Undifferentiated carcinoma of thymus 
0.00 0.00 0.00 36 12 13.3 5.1 34.8 36 
 
  Lymphoepithelial carcinoma of thymus 
0.00 0.00 0.00 12 4 55.0 29.2 103.6 11 
 
  Adenocarcinoma with variants of thymus 
0.00 0.00 0.00 45 15 37.3 21.7 64.1 44 
 
  MALIGNANT MESOTHELIOMA 
2.14 2.12 2.16 33,552 10,868 5.3 4.9 5.6 32,330 
 
  Mesothelioma of pleura and pericardium 
1.83 1.81 1.85 28,676 9,288 4.6 4.2 4.9 27,893 
 
  Mesothelioma of peritoneum and tunica vaginalis 
0.13 0.13 0.14 2,065 669 13.2 11.5 15.1 1,965 
 
Female genital 
rare cancers 
  22.73 22.66 22.81 356151 113,796 57.7 57.5 57.9 347,015 
 
  RARE EPITHELIAL TUMOURS OF BREAST 
4.12 4.09 4.16 64,605 22,980 91.4 91.0 91.8 64,368 
 
  Mammary Paget’s disease of breast 0.41 0.40 0.42 6,488 2,101 85.9 84.6 87.3 6,508 
 
  Special types of adenocarcinoma of breast 
3.06 3.04 3.09 48,012 15,551 95.2 94.8 95.6 47,974 
 
  Metaplastic carcinoma of breast 
0.10 0.10 0.11 1,576 510 65.0 61.9 68.3 1,583 
 
  Salivary gland type tumours of breast 
0.06 0.05 0.06 868 281 90.9 87.6 94.2 870 
 
  Epithelial tumour of male breast 
0.52 0.51 0.53 8,098 5,376 77.0 75.5 78.5 7,882 
 
  RARE EPITHELIAL TUMOURS OF CORPUS UTERI 
0.70 0.69 0.72 11,038 3,932 44.3 43.2 45.5 11,013 
 
  Squamous cell carcinoma with variants of corpus uteri 
0.06 0.06 0.07 1,003 325 58.2 54.6 62.1 989 
 
  Adenoid cystic carcinoma of corpus uteri 
0.00 0.00 0.00 5 2 64.1 31.3 131.1 5 
 
  Clear cell adenocarcinoma, NOS of corpus uteri 
0.16 0.16 0.17 2,527 819 58.6 56.2 61.2 2,532 
 
  Serous (papillary) carcinoma of corpus uteri 
0.08 0.07 0.08 1,227 397 40.0 36.5 43.9 1,225 
 
  Mullerian mixed tumour of corpus uteri 
0.40 0.39 0.41 6,276 2,033 36.9 35.5 38.4 6,263 
 
  EPITHELIAL TUMOURS OF CERVIX UTERI 
6.28 6.24 6.32 98,321 28,898 65.4 65.1 65.8 96,821 
 
  Squamous cell carcinoma with variants of cervix uteri 
4.73 4.70 4.76 74,105 24,003 66.8 66.5 67.2 73,810 
 
  Adenocarcinoma with variants of cervix uteri 
0.91 0.89 0.92 14,252 4,616 67.4 66.5 68.3 14,221 
 
  Undifferentiated carcinoma of cervix uteri 
0.03 0.03 0.03 480 155 35.3 30.9 40.4 478 
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  Mullerian mixed tumour of cervix uteri 
0.02 0.01 0.02 257 83 34.3 28.1 41.7 256 
 
  EPITHELIAL TUMOUR OF OVARY AND FALLOPPIAN 
TUBE 
9.38 9.33 9.43 146,908 45,382 37.5 37.2 37.8 141,240 
 
  Adenocarcinoma with variants of ovary 
5.95 5.92 5.99 93,263 30,208 38.7 38.3 39.1 92,814 
 
  Mucinous adenocarcinoma of ovary 
0.77 0.76 0.78 12,066 3,908 59.9 58.9 60.9 12,010 
 
  Clear cell adenocarcinoma of ovary 
0.30 0.29 0.31 4,753 1,540 55.5 53.8 57.2 4,761 
 
  Primary peritoneal serous/papillary carcinoma of ovary 
0.08 0.08 0.09 1,280 415 21.9 19.1 25.2 1,280 
 
  Mullerian mixed tumour of ovary 
0.14 0.14 0.15 2,255 730 21.4 19.5 23.6 2,242 
 
  Adenocarcinoma with variant of falloppian tube 
0.17 0.16 0.18 2,683 869 59.1 56.8 61.6 2,672 
 
  NON EPITHELIAL TUMOURS OF OVARY 
0.25 0.25 0.26 3977 1288 82.0 80.6 83.5 
3,970 
 
  Sex cord tumours of ovary 
0.13 0.12 0.13 2,006 650 78.8 76.5 81.1 1,998 
 
  Malignant/Immature teratomas of ovary 
0.05 0.05 0.06 833 270 83.4 80.6 86.3 829 
 
  Germ cell tumour of ovary 
0.07 0.07 0.08 1,138 369 86.6 84.4 88.8 1,143 
 
  EPITHELIAL TUMOURS OF VULVA AND VAGINA 
1.97 1.95 2.00 30938 11215 58.1 57.3 58.8 
30,238 
 
  Squamous cell carcinoma with variants of vulva and vagina 
1.69 1.67 1.71 26,422 8,558 59.8 59.0 60.7 26,277 
 
  Adenocarcinoma with variants of vulva and vagina 
0.07 0.07 0.08 1,120 363 45.8 42.3 49.6 1,112 
 
  Paget s disease of vulva and vagina 
0.05 0.04 0.05 746 242 88.0 83.7 92.6 744 
 
  Undifferentiated carcinoma of vulva and vagina 
0.01 0.00 0.01 85 28 25.6 15.8 41.6 85 
 
  TROPHOBLASTIC TUMOUR OF PLACENTA 
0.02 0.02 0.03 363 100 89.3 85.3 92.2 361 
 
  Choriocarcinoma of placenta 
0.02 0.02 0.02 352 114 89.8 86.5 93.3 350 
 
Male genital and 
urogenital rare 
cancers 
  7.09 7.05 7.14 111128 38,138 73.64 73.3 74.0 109,102 
 
  RARE EPITHELIAL TUMOURS OF PROSTATE 
0.60 0.59 0.61 9,437 3,563 75.4 74.0 76.9 9,291 
 
  Squamous cell carcinoma with variants of prostate 
0.02 0.02 0.02 291 94 41.1 34.1 49.5 287 
 
  Infiltrating duct carcinoma of prostate 
0.51 0.50 0.53 8,064 2,612 78.7 77.2 80.3 7,945 
 
  Transitional cell carcinoma of prostate 
0.06 0.06 0.07 960 311 57.7 53.4 62.4 941 
 
  Salivary gland type tumours of prostate 
0.01 0.01 0.01 122 40 78.5 64.4 95.7 118 
 
  TESTICULAR AND PARATESTICULAR CANCERS 
3.29 3.27 3.32 51605 16061 94.9 94.7 95.2 
51,011 
 
  Paratesticular adenocarcinoma with variants 
0.00 0.00 0.00 22 7 82.5 65.3 104.1 22 
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  Non seminomatous testicular cancer 
1.27 1.25 1.28 19,835 6,425 92.9 92.5 93.3 19,714 
 
  Seminomatous testicular cancer 
1.82 1.80 1.84 28,516 9,236 97.5 97.3 97.8 28,326 
 
  Spermatocytic seminoma 
0.03 0.03 0.03 502 163 95.3 91.8 99.0 502 
 
  Teratoma with malignant transformation 
0.00 0.00 0.00 20 6 91.4 78.6 106.2 20 
 
  Testicular sex cord cancer 
0.02 0.02 0.02 340 110 82.3 77.3 87.6 337 
 
  EPITHELIAL TUMOURS OF PENIS 
0.66 0.65 0.67 10368 3887 
67.5 66.2 68.9 10,210 
 
  Squamous cell carcinoma with variants of penis 
0.62 0.60 0.63 9,646 3,124 68.9 67.5 70.2 9,621 
 
  Adenocarcinoma with variants of penis 
0.01 0.00 0.01 88 29 49.0 36.2 66.4 86 
 
  RARE EPITELIAL TUMOURS OF KIDNEY 
0.05 0.04 0.05 723 261 18.8 15.8 22.4 704 
 
  Squamous cell carcinoma spindle cell type of kidney 
0.01 0.01 0.01 190 62 22.0 16.0 30.2 190 
 
  Squamous cell carcinoma with variants of kidney 
0.03 0.03 0.04 533 173 17.7 14.4 21.7 514 
 
  EPITHELIAL TUMOURS OF PELVIS AND URETER 
1.58 1.57 1.60 24826 9187 48.8 48.0 49.7 
24,017 
 
  Transitional cell carcinoma of pelvis and ureter 
1.41 1.39 1.43 22,099 7,158 51.3 50.4 52.2 21,607 
 
  Squamous cell carcinoma with variants of pelvis and ureter 
0.02 0.02 0.03 372 121 15.0 11.2 20.2 366 
 
  Adenocarcinoma with variants of pelvis and ureter 
0.02 0.02 0.02 326 106 43.0 36.7 50.5 320 
 
  EPITHELIAL TUMOURS OF URETHRA 
0.13 0.13 0.14 2077 784 44.5 41.6 47.5 
2,050 
 
  Transitional cell carcinoma of urethra 
0.09 0.08 0.09 1,390 450 42.9 39.5 46.7 1,387 
 
  Squamous cell carcinoma with variants of urethra 
0.02 0.02 0.02 329 107 51.1 44.6 58.5 329 
 
  Adenocarcinoma with variants of urethra 
0.01 0.01 0.01 190 62 52.0 43.2 62.6 189 
 
  RARE EPITHELIAL TUMOURS OF BLADDER 
0.65 0.64 0.67 10226 3819 32.3 31.2 33.5 
10,152 
 
  Squamous cell carcinoma with variants of bladder 
0.36 0.35 0.36 5,566 1,803 24.3 22.9 25.7 5,534 
 
  Adenocarcinoma with variants of bladder 
0.30 0.29 0.31 4,653 1,507 41.9 40.1 43.8 4,614 
 
  Salivary gland type tumours of bladder 
0.00 0.00 0.00 7 2 NE NE NE 7 
 
  EXTRAGONADAL GERM CELL TUMOURS 
0.12 0.11 0.12 1,862 576 69.6 67.3 71.8 1,851 
 
  Non seminomatous germ cell tumours 
0.06 0.05 0.06 915 296 62.5 59.2 66.0 909 
 
  Seminomatous germ cell tumors 
0.01 0.01 0.01 130 42 85.9 79.1 93.3 130 
 
  Germ cell tumors of CNS 
0.04 0.03 0.04 574 186 82.5 79.2 85.9 572 
 
Neuroendocrine 
tumours 
  3.51 3.43 3.58   19587 53.5 53.0 54.1 54,331 
 
  NEUROENDOCRINE TUMOURS 
3.51 3.48 3.54 54942 19587 53.5 53.0 54.1 
54,331 
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GEP, well diff not funct endocrine carcinoma of pancreas and digestive 
tract 
1.01 1.00 1.03 15,852 5,134 72.0 71.1 73.0 15,656 
 
  
GEP, well diff funct endocrine carcinoma of pancreas and digestive 
tract 
0.03 0.02 0.03 411 133 61.3 55.9 67.3 407 
 
  GEP, poorly differentiated endocrine carcinoma 
0.67 0.65 0.68 10,421 3,375 35.0 33.9 36.2 10,456 
 
  GEP, mixed endocrine-exocrine carcinoma 
0.01 0.01 0.01 147 48 25.9 18.2 37.0 141 
 
  Endocrine carcinoma of thyroid gland 
0.24 0.23 0.25 3,796 1,230 83.6 82.1 85.2 3,793 
 
  Neuroendocrine carcinoma of skin 
0.19 0.19 0.20 3,024 979 55.9 53.2 58.7 2,997 
 
  Typical and atypical carcinoid of the lung 
0.39 0.38 0.40 6,160 1,995 81.1 79.9 82.5 6,058 
 
  Neuroendocrine carcinoma of other sites 
0.90 0.89 0.92 14,120 4,573 23.9 23.0 24.8 13,958 
 
  Pheochromocytoma, malignant 
0.04 0.04 0.04 650 211 70.1 65.9 74.5 612 
 
  Paraganglioma 
0.02 0.02 0.02 347 112 56.3 50.6 62.6 342 
 
Cancers of the 
endocrine organs 
  5.35 5.32 5.39 83836 28,322 88.08 87.8 88.4 82,523 
 
  CARCINOMAS OF PITUITARY GLAND 0.04 
0.03 0.04 582 206 63.7 58.9 69.0 511 
 
  Carcinoma of pituitary gland 
0.04 0.03 0.04 582 206 63.7 58.9 69.0 511 
 
  CARCINOMAS OF THYROID GLAND 5.07 
5.03 5.10 79,418 26,768 90.5 90.2 90.8 78,533 
 
  Carcinoma of thyroid gland 
5.07 5.03 5.11 79,420 26,768 90.5 90.2 90.8 78,533 
 
  CARCINOMAS OF PARATHYROID GLAND 0.03 
0.02 0.03 410 143 80.8 75.8 86.2 395 
 
  Carcinoma of parathyroid gland 
0.03 0.02 0.03 410 143 80.8 75.8 86.2 395 
 
  CARCINOMA OF ADRENAL GLAND 0.22 
0.21 0.23 3,424 1,205 32.1 30.2 34.0 3,103 
 
  Carcinoma of adrenal gland 
0.22 0.21 0.23 3,424 1,205 32.1 30.2 34.0 3,103 
 
Sarcomas   5.86 
5.83 6.00 91878 31,916 59.53 57.4 58.2 90,568 
 
  SOFT TISSUE SARCOMA 
4.71 4.68 4.74 73,795 25,851 56.7 56.3 57.1 
72,696 
 
  Soft tissue sarcoma of head and neck 
0.26 0.25 0.27 4,087 1,324 59.8 57.7 61.8 4,062 
 
  Soft tissue sarcoma of limbs 
1.10 1.08 1.11 17,178 5,564 67.7 66.8 68.6 17,094 
 
  Soft tissue sarcoma of superficial trunk 
0.50 0.49 0.51 7,813 2,531 48.1 46.8 49.5 7,723 
 
  Soft tissue sarcoma of mediastinum 
0.03 0.03 0.03 465 151 23.4 19.3 28.3 457 
 
  Soft tissue sarcoma of heart 
0.01 0.01 0.02 216 70 14.4 9.8 21.0 203 
 
  Soft tissue sarcoma of breast 
0.18 0.18 0.19 2,865 928 74.5 72.5 76.5 2,864 
 
  Soft tissue sarcoma of uterus 
0.55 0.54 0.56 8,657 2,804 52.0 50.8 53.2 8,568 
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  Other soft tissue sarcomas of genitourinary tract 
0.20 0.19 0.21 3,160 1,024 50.4 48.3 52.5 3,107 
 
  Soft tissue sarcoma of viscera 
0.38 0.37 0.39 6,004 1,945 42.1 40.6 43.6 5,915 
 
  Soft tissue sarcoma of paratestis 
0.03 0.03 0.04 510 165 87.2 82.2 92.4 510 
 
  Soft tissue sarcoma of retroperitoneum and peritoneum 
0.31 0.30 0.32 4,911 1,591 38.8 37.1 40.5 4,854 
 
  Soft tissue sarcoma of pelvis 
0.20 0.19 0.20 3,090 1,001 47.4 45.3 49.6 3,064 
 
  Soft tissue sarcoma of skin 
0.30 0.29 0.31 4,737 1,534 90.2 88.8 91.7 4,728 
 
  Soft tissue sarcoma of paraorbit 
0.01 0.01 0.01 117 38 63.3 52.9 75.7 115 
 
  Soft tissue sarcoma of brain and other parts of nervous system 
0.17 0.17 0.18 2,723 882 54.5 52.3 56.7 2,695 
 
  Embryonal rhabdomyosarcoma of soft tissue 
0.05 0.05 0.06 836 271 66.2 62.8 69.8 825 
 
  Alveolar rhabdomyosarcoma of soft tissue 
0.03 0.03 0.04 519 168 36.0 31.7 40.8 515 
 
  Ewing’s sarcoma of soft tissue 0.06 0.06 0.07 998 323 44.9 41.5 48.5 992 
 
  BONE SARCOMA 
0.85 0.84 0.87 13,376 4,382 58.6 57.6 59.6 
13,216 
 
  Osteogenic sarcoma 
0.21 0.21 0.22 3,330 1,079 51.4 49.5 53.4 3,282 
 
  Chondrogenic sarcomas 
0.26 0.25 0.27 4,107 1,330 70.0 68.2 71.7 4,060 
 
  Notochordal sarcomas, chordoma 
0.07 0.07 0.08 1,145 371 62.5 58.2 67.2 755 
 
  Vascular sarcomas 
0.01 0.01 0.01 129 42 45.1 36.4 55.9 129 
 
  Ewing’s sarcoma 0.12 0.12 0.13 1,943 629 52.8 50.4 55.3 1,932 
 
  Epithelial tumours, adamantinoma 
0.01 0.01 0.02 213 69 87.2 81.0 93.9 210 
 
  
Other high grade sarcomas (fibrosarcoma, malignant fibrous 
histiocytoma) 
0.02 0.02 0.02 304 98 46.2 40.1 53.1 302 
 
  GASTROINTESTINAL STROMAL SARCOMA 
0.30 0.29 0.31 4706 1683 72.3 70.4 74.1 
4,781 
 
  Gastrointestinal stromal sarcoma 
0.30 0.29 0.31 4,706 1,524 72.3 70.4 74.1 4,781 
 
Cancers of the 
central nervous 
system (CNS) 
  7.56 7.51 8.00 118391 36,343 21.3 21.0 21.6 111,838 
 
  TUMOURS OF CENTRAL NERVOUS SYSTEM (CNS)** 
7.36 7.32 7.40 115,289 35,339 20.3 20.0 20.6 108,752 
 
  Astrocytic tumours of CNS 
4.99 4.95 5.02 78,118 25,303 15.0 14.8 15.3 77,195 
 
  Oligodendroglial tumours of CNS 0.39 0.38 0.40 6,148 1,991 51.8 50.4 53.3 6,124 
 
  Ependymal tumours of CNS 
0.21 0.20 0.21 3,212 1,040 72.7 71.0 74.5 3,190 
 
  Choroid plexus carcinoma of CNS 
0.01 0.01 0.01 98 32 57.7 48.3 68.8 95 
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  Malignant meningiomas 
0.16 0.16 0.17 2,564 830 61.1 58.8 63.4 2,509 
 
  EMBRYONAL TUMORS OF CNS 
0.20 0.19 0.21 3,102 1,005 56.1 54.2 58.1 3,092 
 
  Embryonal tumors of CNS 
0.20 0.19 0.21 3,102 1,005 56.1 54.2 58.1 3,092 
 
Rare skin 
cancers and non-
cutaneous 
melanoma 
  1.22 1.18 1.25   7,086 70.2 69.3 71.1 21,637 
 
  MALIGNANT MELANOMA OF MUCOSA 
0.15 0.14 0.15 2,279 738 20.3 18.2 22.6 2,277 
 
  Malignant melanoma of mucosa 0.15 0.14 0.15 2,279 738 20.3 18.3 22.6 2,277 
 
  MALIGNANT MELANOMA OF UVEA 
0.70 0.69 0.72 11,022 3,570 71.0 69.8 72.2 10,872 
 
  Malignant melanoma of uvea 
0.70 0.69 0.72 11,022 3,570 71.0 69.8 72.2 10,872 
 
  ADNEXAL CARCINOMA OF SKIN 0.30 0.29 0.31 4,684 1,517 86.1 83.9 88.0 4,661 
 
  Adnexal carcinoma of skin 
0.30 0.29 0.31 4,684 1,517 86.1 83.9 88.0 4,661 
 
  KAPOSI'S SARCOMA 
0.25 0.24 0.26 3,893 1,261 78.9 77.0 80.7 3,830 
 
  Kaposi's sarcoma 0.25 0.24 0.26 3,893 1,261 78.9 77.1 80.8 3,830 
 
Embrional 
tumours  
  0.34 0.33 0.35 5363 1,822 78.6 77.4 79.8 5,239 
 
  NEUROBLASTOMA AND GANGLIONEUROBLASTOMA 
0.10 0.10 0.11 1566 499 64.6 62.1 67.3 
1,553 
 
  Neuroblastoma e ganglioneuroblastoma 0.10 0.10 0.11 1,566 507 64.6 62.1 67.3 1,553 
 
  NEPHROBLASTOMA 
0.13 0.12 0.13 1,965 636 88.2 86.6 89.7 1,936 
 
  Nephroblastoma 
0.13 0.12 0.13 1,965 636 88.2 86.6 89.7 1,936 
 
  RETINOBLASTOMA 0.05 0.05 0.06 860 279 96.5 95.1 97.9 801 
 
  Retinoblastoma 
0.05 0.05 0.06 860 279 96.5 95.1 97.9 801 
 
  HEPATOBLASTOMA 
0.02 0.02 0.03 357 116 76.8 72.2 81.7 352 
 
  Hepatoblastoma 0.02 0.02 0.03 357 116 76.8 72.2 81.7 352 
 
  PLEUROPULMONARY BLASTOMA 
0.02 0.02 0.03 357 116 76.8 72.2 81.7 352 
 
  Pleuropulmonary blastoma 
0.00 0.00 0.00 9 3 53.5 28.3 101.1 9 
 
  PANCREATOBLASTOMA 0.00 0.00 0.00 9 3 53.5 28.3 101.1 9 
 
  Pancreatoblastoma 
0.00 0.00 0.00 39 13 34.3 20.7 56.9 35 
 
  OLFACTORY NEUROBLASTOMA 
0.00 0.00 0.00 39 13 34.3 20.7 56.9 35 
 
  Olfactory neuroblastoma 0.03 0.03 0.03 498 161 64.0 59.2 69.2 489 
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  ODONTOGENIC MALIGNANT TUMOURS 
0.03 0.03 0.03 498 161 64.0 59.2 69.2 489 
 
  Odontogenic malignant tumours 
0.00 0.00 0.01 69 22 61.6 49.0 77.5 69 
 
Haematological 
rare 
malignancies 
  27.73 27.65 27.82 434469 156,099 50.5 50.3 50.7 423,741 
 
  RARE LYMPHOID DISEASES 
18.09 18.02 18.16 283,399 100,343 55.8 55.5 56.0 279,794 
 
  Hodgkin lymphoma, classical 
2.46 2.44 2.49 38,588 12,499 81.4 80.9 81.8 38,389 
 
  Hodgkin lymphoma nodular lymphocyte predominance 
0.09 0.09 0.10 1,483 480 93.6 91.8 95.3 1,507 
 
  
Precursor B/T lymphoblastic leuk/lymphoma (and Burkitt 
leukemia/lymphoma) 
1.46 1.44 1.47 22,795 7,383 58.1 57.4 58.8 22,496 
 
  T cutaneous lymphoma (Sezary syn, Mycosis fung) 
0.35 0.34 0.36 5,526 1,790 81.5 80.0 83.1 5,482 
 
  Other T cell lymphomas and NK cell neoplasms 
0.62 0.60 0.63 9,656 3,128 39.0 37.9 40.2 9,635 
 
  Diffuse B lymphoma 
4.32 4.29 4.35 67,645 21,910 53.4 52.9 53.9 67,907 
 
  Follicular B lymphoma 
2.19 2.17 2.22 34,346 11,125 77.0 76.4 77.6 34,545 
 
  Hairy cell leukaemia 
0.28 0.27 0.29 4,375 1,417 89.8 88.3 91.3 4,387 
 
  Plasmacytoma/Multiple Myeloma (and Heavy chain diseases) 
5.71 5.67 5.75 89,440 28,970 35.3 34.8 35.7 86,496 
 
  Mantle cell lymphoma 
0.56 0.55 0.57 8,748 2,834 44.0 42.6 45.4 8,797 
 
  Prolymphocytic leukaemia, B cell 
0.05 0.05 0.06 804 260 30.8 26.9 35.2 788 
 
  
ACUTE MYELOID LEUKEMIA AND RELATED PRECURSOR 
NEOPLASMS 
3.81 3.77 3.84 59,608 21,557 
19.2 18.8 19.6 56,709 
 
  Acute promyelocytic leukemia (AML with t(15;17) with variants 
0.12 0.11 0.13 1,876 608 63.2 60.8 65.7 1,880 
 
  Acute myeloid leukemia 
3.50 3.47 3.53 54,789 17,746 17.5 17.1 17.8 52,305 
 
  MYELOPROLIFERATIVE NEOPLASMS 
3.31 3.28 3.34 51888 18805 68.3 67.7 68.9 50,624 
 
  Chronic myeloid leukemia 
1.12 1.10 1.13 17,473 5,660 54.9 54.0 55.9 16,599 
 
  Other myeloproliferative neoplasms 
2.17 2.14 2.19 33,954 10,998 75.0 74.3 75.7 33,599 
 
  Mast cell tumour 
0.03 0.03 0.03 461 149 71.4 66.2 77.1 454 
 
  
MYELODYSPLASTIC SYNDROME AND 
MYELODYSPLASTIC/MYELOPROLIFERATIVE DISEASES 
2.47 2.45 2.50 38,738 15,116 31.1 30.5 31.8 37,792 
 
  Myelodysplastic syndrome with 5q syndrome 
0.01 0.01 0.01 156 51 48.0 38.3 60.3 178 
 
  Other myelodysplastic syndrome 
2.14 2.12 2.16 33,542 10,864 32.2 31.5 32.9 32,576 
 
  Chronic Myelomonocytic leukemia 
0.29 0.28 0.30 4,542 1,471 21.3 19.8 23.0 4,575 
 
  Atypical chronic myeloid leukemia BCR/ABL negative 
0.02 0.01 0.02 239 77 28.2 21.7 36.5 248 
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  HISTIOCYTIC AND DENDRITIC CELL NEOPLASMS 
0.05 0.05 0.06 828 278 59.9 56.1 63.9 817 
 
  Histiocytic malignancies 
0.04 0.04 0.05 656 212 63.4 59.4 67.8 645 
 
  Lymph node accessory cell tumors 
0.01 0.01 0.01 172 56 45.6 37.1 56.0 172 
 
All rare tumours ALL RARE TIER2 TUMOURS  114.99 114.82 115.16 1,801,443 
636753 
48.5 48.4 48.6 1,751,601 
 
COMMON CANCERS 
         
 
Digestive 
common 
tumours 
  91.80 91.65 91.95 1,438,094 490,051 41.4 41.3 45.8 1365575 
 
  EPITHELIAL TUMOURS OF STOMACH 17.10 17.03 17.16 267,832 92,067 21.2 21.0 21.4 253,439 
 
  Adenocarcinoma with variants of stomach 14.18 14.12 14.24 222,145 71,954 22.7 22.5 22.9 221,604 
 
  EPITHELIAL TUMOUR OF COLON 43.88 43.77 43.98 687,386 234,319 54.2 54.0 54.4 664,118 
 
  Adenocarcinoma with variants of colon 38.85 38.75 38.95 608,637 197,139 57.9 57.7 58.0 604,459 
 
  EPITHELIAL TUMOURS OF RECTUM 17.98 17.92 18.05 281,697 95,187 53.8 53.6 54.1 276,024 
 
  Adenocarcinoma with variants of rectum 16.45 16.39 16.52 257,723 83,477 55.8 55.6 56.1 258,469 
 
  EPITHELIAL TUMOURS OF PANCREAS 12.84 12.79 12.90 201,179 68,478 4.1 4.0 4.2 182,579 
 
  Adenocarcinoma with variants of pancreas 7.96 7.92 8.01 124,744 40,405 4.1 4.0 4.2 119,154 
 
Thoracic 
common 
tumours 
  53.02 52.91 53.14 830,611 281,332 10.1 10.0 10.2 779,539 
 
  EPITHELIAL TUMOUR OF LUNG 53.02 52.91 53.14 830,611 281,332 10.1 10.0 10.2 779,539 
 
  Squamous cell carcinoma with variants of lung 12.31 12.25 12.36 192,771 62,439 5.9 13.7 14.1 121,904 
 
  Adenocarcinoma with variants of lung 11.63 11.58 11.68 182,175 59,007 40.4 15.9 16.3 866 
 
  Poorly differentiated endocrine carcinoma of lung 7.91 7.86 7.95 123,888 40,128 17.5 5.7 6.0 3,183 
 
Female genital 
common 
tumours 
  74.17 74.03 74.30 1,161,864 394,087 82.20 82.10 82.30 1,131,902 
 
  EPITHELIAL TUMOURS OF BREAST 63.52 63.40 63.65 995,119 318,878 82.4 82.3 82.5 971,037 
 
  Invasive ductal carcinoma of breast 46.56 46.45 46.66 729,345 236,237 85.4 85.3 85.6 723,998 
 
  Invasive lobular carcinoma of breast 7.75 7.71 7.80 121,455 39,340 86.2 85.9 86.5 120,973 
 
  EPITHELIAL TUMOURS OF CORPUS UTERI 10.64 10.59 10.70 166,745 75,209 81.2 80.9 81.4 164,787 
 
  Adenocarcinoma with variants of corpus uteri 9.93 9.88 9.98 155,550 50,383 83.0 82.7 83.2 154,968 
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Male genital and 
urogenital 
common 
tumours 
  85.27 85.13 85.42 1,335,876 462,665 75.90 75.80 76.00 1,277,743 
 
  EPITHELIAL TUMOURS OF PROSTATE 55.06 54.95 55.18 862,576 301,113 84.0 83.8 84.1 842,467 
 
  Adenocarcinoma with variants of prostate 48.86 48.75 48.97 765,405 247,917 88.1 88.0 88.3 762,360 
 
  EPITELIAL TUMOURS OF KIDNEY 12.66 12.61 12.72 198,402 65,848 60.5 60.2 60.7 187,324 
 
  Renal cell carcinoma with variants 10.08 10.03 10.13 157,886 51,140 68.5 68.2 68.8 153,460 
 
  EPITHELIAL TUMOURS OF BLADDER 17.55 17.48 17.61 274,896 95,704 60.4 60.1 60.6 266,941 
 
3 Transitional cell carcinoma of bladder 15.68 15.62 15.74 245,681 79,577 62.7 62.4 63.0 243,620 
 
                      
 
Common skin 
tumours and 
non-cutaneous 
melanoma 
  69.08 68.95 69.21 1,082,244 350,542 95.60 95.50 95.70 1,048,046 
 
  MALIGNANT SKIN MELANOMA 14.06 14.00 14.12 220,206 71,325 83.8 83.6 84.0 216317 
 
  Malignant skin melanoma 14.06 14.00 14.12 220,206 71,325 83.8 83.6 84.1 216,317 
 
  EPITHELIAL TUMOURS OF SKIN 55.03 54.91 55.14 862,038 279,217 98.8 98.7 99 837,895 
 
  Basal cell carcinoma of skin 40.75 40.65 40.85 638,347 206,763 101.6 101.5 101.8 634,953 
 
  Squamous cell carcinoma with variants of skin 14.28 14.22 14.34 223,691 72,454 89.7 89.4 90.1 221,487 
 
Haematological 
common 
malignancies 
  11.03 10.98 11.08 172,794 58,286 60.5 60.2 60.8 166,040 
 
  LYMPHOID DISEASES 
11.03 10.98 11.08 172794 58286 60.5 60.2 60.8 166040 
 
  Other non Hodgkin, Mature B cell lymphoma 6.37 6.33 6.41 99,729 32,303 68.3 67.8 68.7 97,389 
 
All common 
tumours 
ALL COMMON  384.37 384.07 384.68 6,021,483 2,036,963 63.4 63.3 63.4 5633710 
 
Note: the first tier entities (capital letters) are not a sum of the second tiers (small letters) included because of the NOS entities 
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Table 2. Age standardized incidence in 1999-2002 and 2003-2007, and corresponding Annual Percent Changes  (APC) between the two periods, of rare cancers lying outside the 3-
standard-errors confidence bounds in Figure  
 
Table 2. Variations over time in age adjusted incidence rates of rare cancers lying outside the confidence bounds in Figure 1 
  
      Cancer entity 1999-2002 2003-2007 APC Confidence limits 
Gastrointestinal stromal sarcoma 0.098 0.258 24.1 12.0 36.2 
GEP, Poorly differentiated endocrine carcinoma of pancreas and digestive system 0.361 0.618 12.7 7.7 17.8 
Other T cell lymphomas and NK cell neoplasms 0.395 0.555 7.8 3.3 12.4 
Diffuse B lymphoma 2.837 3.894 7.3 5.7 8.9 
Other myeloproliferative neoplasms 1.530 2.092 7.2 5.0 9.4 
Mantle cell lymphoma 0.367 0.477 6.0 1.6 10.4 
Carcinomas of thyroid gland 3.470 4.353 5.2 3.7 6.6 
Other myelodysplastic syndrome 1.395 1.738 5.0 3.0 7.1 
Squamous cell carcinoma with variants of anal canal 0.595 0.728 4.6 1.2 8.0 
Follicular B lymphoma 1.676 2.021 4.2 2.2 6.3 
Cholangiocarcinoma of IBT 0.685 0.816 4.0 0.9 7.0 
Neuroendocrine carcinoma of other sites 0.683 0.801 3.6 0.5 6.7 
Adenocarcinoma with variants of oesophagus 2.725 3.153 3.3 1.8 4.8 
Squamous cell carcinoma with variants of oropharynx 2.412 2.732 2.8 1.1 4.5 
Adenocarcinoma with variants of EBT 0.969 1.088 2.6 0.1 5.1 
Hepatocellular carcinoma of Liver and IBT 2.068 2.273 2.1 0.4 3.8 
Squamous cell carcinoma with variants of cervix uteri 4.536 4.287 -1.2 -2.4 -0.1 
Adenocarcinoma with variants of ovary 5.351 5.053 -1.3 -2.3 -0.2 
Squamous cell carcinoma with variants of larynx 3.853 3.578 -1.6 -2.8 -0.4 
Chronic myeloid leukemia 0.991 0.854 -3.2 -5.5 -0.9 
Infiltrating duct carcinoma of prostate 0.412 0.343 -4.0 -7.4 -0.6 
Squamous cell carcinoma with variants of lip 0.838 0.693 -4.1 -6.5 -1.8 
Large cell carcinoma of lung 3.440 2.806 -4.4 -5.6 -3.2 
Mucinous adenocarcinoma of ovary 0.813 0.657 -4.6 -7.2 -2.1 
Adenocarcinoma with variants of bladder 0.265 0.213 -4.7 -8.9 -0.5 
Undifferentiated carcinoma of stomach 0.189 0.123 -9.2 -13.9 -4.5 
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Table 3. Variations over time  in age adjusted 5-year relative survival of rare cancers lying outside the confidence bounds in Figure 2 
Table 3. Age standardized 5-year relative survival in 1999-2001 and 2005-2007, and corresponding 
difference between the two periods, of rare cancers lying outside the 3-standard-errors confidence 
bounds in Figure 1 
 
       1999-2001 2005-2007       
Entity 5-year surv 5-year surv Difference lower upper 
Chronic myeloid leukemia 37.2 57.9 20.7 17.4 24.1 
Infiltrating duct carcinoma of prostate 67.5 79.8 12.3 6.4 18.2 
Soft tissue sarcoma of viscera 34.7 43.7 9.0 3.6 14.4 
Kaposi's sarcoma 75.4 84.2 8.8 1.4 16.2 
Diffuse B lymphoma 46.9 55.2 8.4 6.5 10.2 
Follicular B lymphoma 69.5 77.9 8.4 5.9 10.8 
GEP, Poorly differentiated endocrine carcinoma of pancreas and digestive system 25.3 32.7 7.5 2.7 12.2 
Squamous cell carcinoma with variants of oropharynx 37.5 44.5 7.1 5.0 9.2 
Soft tissue sarcoma of superficial trunk 43.9 50.4 6.5 1.4 11.6 
Precursor B/T lymphoblastic leukemia/lymphoma (and Burkitt leukemia/lymphoma) 54.3 60.8 6.4 3.8 9.1 
Plasmacytoma/Multiple Myeloma (and Heavy chain diseases) 29.8 35.0 5.2 3.8 6.7 
Carcinomas of thyroid gland 85.6 90.6 5.0 3.8 6.3 
Adenocarcinoma with variants of cervix uteri 63.8 68.8 5.0 1.7 8.3 
GEP, Well differentiated not functing endocrine carcinoma of pancreas and digestive system  67.7 72.6 4.9 1.5 8.4 
Soft tissue sarcoma of limbs 63.9 68.4 4.4 1.0 7.9 
Adenocarcinoma with variants of oesophagus 9.9 13.8 3.9 2.6 5.1 
Squamous cell carcinoma with variants of oral cavity 46.1 49.7 3.7 1.7 5.6 
Squamous cell carcinoma with variants of hypopharynx 22.2 25.6 3.4 0.5 6.3 
Other myeloproliferative neoplasms 70.8 74.0 3.2 0.6 5.9 
Squamous cell carcinoma with variants of cervix uteri 65.1 68.1 3.0 1.6 4.5 
Large cell carcinoma of lung 10.9 13.6 2.7 1.6 3.9 
Adenocarcinoma with variants of EBT 16.2 18.7 2.6 0.2 5.0 
Squamous cell carcinoma with variants of oesophagus 9.5 12.0 2.5 1.3 3.7 
Hepatocellular carcinoma of Liver and IBT 11.0 13.0 2.0 0.5 3.5 
Other myelodysplastic syndrome 33.8 30.2 -3.5 -6.3 -0.8 
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Table 4. Annual number of cases, number of hospitals providing 75% of treatments (H75), mean annual number of treatments (treat) provided by H75 hospitals, by 
country and cancer group 
 
Country, population (millions) 
Group Belgium (10.5) Bulgaria (7.7) Finland (5.3) Ireland (4.2) 
Netherlands 
(16.3) Slovenia (2.0) Navarra (0.6) 
 
cases H75 treat cases H75 treat cases H75 treat cases H75 treat cases H75 treat cases H75 treat cases H75 treat 
Haed & Neck 2,098 29 105.6 1,180 10 145.1 439 6 82.2 368 7 63.0 2,439 12 201.4 395 2 266.1 125 2 76.6 
Epithelial Ovary 760 50 19.5 627 16 52.3 370 10 44.5 261 15 21.0 1,118 47 30.2 158 3 82.0 38 1 45.5 
Oesophagus 689 31 29.3 77 14 5.2 163 8 21.6 289 9 37.1 1,422 31 42.0 49 2 32.9 24 2 15.7 
Central Nervous System 623 20 48.4 412 13 41.7 57 4 19.1 229 3 106.3 912 14 84.0 97 2 78.7 47 2 32.0 
Soft Tissue Sarcoma 500 35 16.6 372 21 18.4 165 7 25.6 157 17 10.6 802 33 26.4 81 2 47.4 32 2 17.4 
Thyroid 576 34 14.2 220 12 20.4 286 12 22.8 98 11 9.6 418 31 17.1 109 1 260.3 43 2 36.8 
Testis 244 40 8.4 180 19 12.4 101 9 14.3 144 12 15.6 609 42 18.4 93 3 48.8 10 3 4.4 
Biliary Tract 214 44 4.9 183 23 6.5 147 13 11.3 122 14 7.7 582 38 12.2 47 3 13.2 43 2 19.7 
GEP 287 46 5.6 30 21 1.3 148 13 9.3 61 20 2.7 355 44 6.9 22 3 6.8 10 3 2.9 
Liver 250 22 11.0 107 12 7.6 165 11 12.8 68 12 4.6 236 36 5.2 29 2 14.4 49 3 14.5 
Urinary Tract 292 48 6.7 67 17 4.1 48 12 3.9 24 10 2.3 419 46 7.7 30 3 8.9 19 3 8.2 
Mesothelioma 184 25 8.7 34 10 3.7 64 9 6.8 25 11 2.0 481 43 9.8 21 1 22.3 9 2 4.6 
Vagina 172 35 5.8 120 9 14.0 70 5 14.8 40 9 4.7 296 14 21.8 42 2 21.9 8 2 4.7 
Bone Sarcoma 81 10 10.2 55 13 4.6 28 3 9.6 30 7 5.2 195 5 43.3 15 2 10.4 3 2 2.4 
Anal Canal 95 27 5.3 39 12 4.1 24 7 4.6 30 9 4.4 135 22 7.2 15 1 23.6 4 2 3.6 
Melanoma of uvea 43 2 21.9 17 7 2.7 6 1 5.5 29 4 5.7 156 2 80.2 13 1 11.9 3 3 0.8 
Penis 63 43 1.4 39 17 2.4 21 10 2.1 20 15 1.2 109 26 3.7 9 4 2.0 4 3 1.2 
Small Intestine 62 37 1.9 15 13 1.1 26 13 2.1 27 20 1.3 120 38 2.6 5 4 1.3 2 2 1.0 
Neuroendocrine carcinoma of 
skin 46 32 1.9 1 3 0.4 0 
  
15 18 0.8 77 37 2.3 4 4 1.1 0 
 
  
Non epithelial Ovary 20 19 1.3 43 17 3.2 8 9 1.1 8 15 0.6 32 24 1.4 4 3 1.7 1 3 0.3 
Endocrine carcinoma of thyroid 31 22 1.4 10 9 1.2 8 8 1.2 5 10 0.5 32 13 2.7 5 1 10.3 1 1 1.7 
Thymus 22 20 1.4 7 8 1.3 4 5 1.1 5 5 1.3 36 15 2.8 3 2 2.1 2 2 1.3 
Nephroblastoma 18 4 7.4 6 3 2.8 8 3 4.7 7 1 13.4 30 4 16.9 3 1 4.8 0 1 0.3 
Melanoma of mucosa 14 24 0.8 2 5 0.8 10 7 1.7 6 11 0.6 34 13 3.0 4 3 1.5 1 2 0.3 
Adrenal cortex 13 14 1.1 13 10 1.3 6 7 0.9 5 11 0.4 25 15 1.5 3 2 1.4 1 2 0.4 
Embryonal CNS 21 9 4.2 14 9 2.5 6 3 3.1 9 3 6.3 0 
  
  2 4.2 2 1 5.2 
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Neuroblastoma 15 4 5.7 8 5 1.7 1 1 2.1 7 2 5.4 12 4 6.2 1 2 1.3 1 1 1.8 
Retinoblastoma 10 1 14.0 3 5 0.5 3 2 1.5 3 2 1.8 22 1 30.7 1 1 1.1 1 2 0.5 
Trachaea 10 18 0.9 5 4 1.1 4 5 0.9 2 4 0.4 11 11 1.1 3 1 3.8 1 1 0.5 
  
42 
 
 
 
Table S1.  Annual number of cases observed, Expected  Mean Admission Volume (MAV) level estimated and Estimated  MAV indicator, by cancer, from the pool of the 
seven countries. Detailed estimated  MAV indicator, by cancer and country   
Group of cancer Cases 
Estimated MAV 
POOL Belgium Bulgaria Finland Ireland Netherlands Slovenia Navarra 
Haed & Neck 6749 82.6 45.8 86.5 32.5 66.8 94.2 218.4 38.1 
Epithelial Ovary 3102 20.0 10.6 30.3 17.7 11.3 12.8 62.2 16.2 
Oesophagus 2168 23.0 17.0 3.7 8.8 37.5 27.2 22.7 4.6 
Central Nervous System 2144 35.4 21.0 29.0 8.7 61.4 35.9 57.7 12.1 
Soft Tissue Sarcoma 1968 11.9 9.6 11.1 11.3 7.1 15.4 19.2 6.3 
Thyroid 1669 21.3 14.3 16.7 18.1 9.3 11.6 75.3 13.6 
Testis 1369 13.3 4.6 7.4 7.2 10.9 10.4 46.9 2.2 
Biliary Tract 838 6.4 4.7 6.2 5.3 2.6 7.8 14.5 7.2 
Urinary Tract 816 4.1 3.5 3.8 2.1 1.4 4.6 10.3 3.7 
GEP 763 4.2 4.0 1.1 6.7 1.3 3.8 5.7 1.5 
Vagina 701 7.5 3.0 9.3 5.9 3.9 11.4 11.0 2.5 
Liver 566 7.1 9.7 6.6 5.5 3.5 7.0 5.4 2.3 
Mesothelioma 530 5.3 5.2 2.5 3.2 1.2 5.8 12.3 2.3 
Bone Sarcoma 387 10.8 5.5 4.1 5.3 3.8 21.9 5.4 1.0 
Anal Canal 322 4.2 2.7 2.3 2.0 4.5 5.7 9.2 1.2 
Penis 254 4.0 1.0 1.8 1.1 0.9 10.4 2.7 1.0 
Melanoma of uvea 245 21.1 12.4 1.8 4.5 3.1 39.5 6.9 0.6 
Small Intestine 200 1.2 1.2 1.0 1.3 0.5 1.5 1.2 1.0 
Neuroendocrine carcinoma of skin 135 1.0 0.9 0.3 
 
0.7 1.3 0.9              
Non epithelial Ovary 113 1.1 0.8 2.0 0.5 0.4 0.9 1.1 0.2 
Endocrine carcinoma of thyroid 87 1.4 1.2 0.9 0.7 0.4 1.6 4.0 0.6 
Thymus 74 1.0 0.7 0.8 0.4 0.8 1.4 1.3 0.6 
Nephroblastoma 71 4.0 3.3 1.8 1.6 6.1 5.9 2.1 0.2 
Melanoma of mucosa 65 0.9 0.4 0.4 0.8 0.6 1.4 1.0 0.2 
Embryonal CNS 55 2.3 1.6 1.6 1.0 4.4 
 
2.6 1.5 
Adrenal cortex 54 0.9 0.7 1.6 0.4 0.3 1.1 1.2 0.2 
Neuroblastoma 43 2.2 1.8 1.7 0.6 3.6 2.3 0.7 0.7 
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Retinoblastoma 41 7.7 4.9 0.4 1.3 2.2 14.8 0.7 0.2 
Trachaea 33 0.8 0.4 1.0 0.4 0.4 0.8 2.1 0.3 
Eye 21 0.7 0.3 0.7 0.1 0.3 1.1 0.9 0.4 
Olfactory Neuroblastoma 17 0.5 0.5 0.7 0.4 0.2 0.7 0.3              
Placenta 14 0.4 0.3 0.4 0.2 0.1 0.5 0.1 0.2 
Hepatoblastoma 10 1.0 0.6 0.5 0.3 1.5 1.2 0.4              
Middle ear 10 0.4 0.4 0.6 0.2 0.3 0.5 0.1              
Parathyroid 9 0.3 0.3 0.5 0.3 0.2 0.5 0.1 0.2 
Pituitary 3 0.2 0.3 
 
0.3 0.2 0.3 
 
             
Parcreatoblastoma 1 0.3   0.3 
    
             
Pleuropulmonary blastoma 0 0.2     0.1   0.3                
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Manuscript reference number: THELANCETONCOLOGY-D-17-00424 
Title: Burden, time trends and centralized treatment of rare tumors: a European perspective. The 
RARECAREnet Project 
Replies to Reviewer 1 
 
This is a very interesting study addressing the incidence or rare cancers in EU, by pooling together the 
data from cancer registries collected in 90' and 00'. This represents a follow-up of a previous effort, by 
an experienced group, with addition information on evolution of incidence and 5-year survival. The 
limits of the methods are described and carefully considered . The results are of importance at the time 
of the ERN as rightly pointed out. The following points need to be addressed to improve the quality of 
the manuscript. 
 
Major points: 
 
1. I noted imprecisions and non-consistent data in the first tables. For instance, the incidence of 
gastrointestinal stromal sarcoma (GIST) is 0.30, notably inferior to what is known now. There may be 
overlaps between organ based classification ( eg gyne) and histologies (NET, sarcoma; eg : getting 
back to the same example, are gist also present in visceral sarcoma?  
Replay: It is true, incidence of GIST is underestimated. This was recognized in several papers studying 
GIST from population-based data. The new ICD-O code of GIST was at the beginning underused   by 
pathologists. However, its use is increasing, as suggested by the growing trend (Fig and Table ).We 
can mainly attribute the rising incidence trend for GIST to the introduction of the new code and to its 
rising use in Europe. Now, we have stressed more the point in the discussion, page14. There is no 
overlapping use of ICD-O codes in our rare cancers classification, thus GIST is not included in visceral 
sarcoma, nor NET in epithelial tumours, and so on.  
2. The writing is often technical for a mostly oncology reader. For instance, to which extent DCO, MAV 
are commonly used criteria in other published experience. This could be improved relatively easily. 
Replay: We tried to remove throughout the manuscript all the unnecessary technicalities. In particular, 
we tried to make more clear the use of the MAV indicator that, to our knowledge, has been for the first 
time used in this work.  
3. A more precise discussion on what should be done to monitor better incidence and 5-year survival 
rate, in the discussion section would be very useful. 
Replay: We expanded this issue in the discussion (page 20). 
4. More detailed legends would be useful for the figures 
Replay: we have improved them.  
 
Minor points 
*Reply to Reviewers Comments
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1. The discussion could be condensed and shortened. 
Replay: we little shortened the discussion.  
 
 
Reviewer #2: General comments 
 
Much of what is presented here simply updates and refreshes these authors' previous publication in the 
European Journal of Cancer. What is novel is the attempt to estimate the extent to which, in different 
jurisdictions, the treatment of rare cancers is centralised. This is an important contribution to our 
knowledge concerning how best to organise cancer services and will, in the future, prove useful in 
assessing the effects of increased or decreased centralisation on outcomes for patients with rare 
cancers. 
Replay:  We agree, and we also provided for the first time incidence and survival trends. We intended 
to provide a baseline analysis relevant to the European efforts on rare cancers with the Joint Action and 
the European Reference Network. 
  
Nearly one quarter of all cancers in Europe are rare cancers: the definition used here is of 6/100,000. 
Others have used absolute prevalence of 200,000 (FDA) or <15/100,000 (Greenlee et al 2010). 
Estimates of rare cancer incidence will depend critically on the criteria used for lumping and splitting 
within the ICDO classification. If head and neck cancer were to be considered as a group of tumours, 
rather than as 17 separate entities, then its incidence rate at 18.2/100,000 is well above any of these 
thresholds. 
Replay:  In the US, the American Cancer Society adopted our cut off for its recent report 
https://www.cancer.org/research/cancer-facts-statistics/all-cancer-facts-figures/cancer-facts-figures-
2017.html. The same was for the Japanese and other European countries papers.  
Actually, epithelial H&N tumours are considered as both a single broad family including, 17 clinically 
distinct rare entities. This example is now better clarified at page 10. This point addresses the structure 
of rare cancers classification. The first paragraph added to the Method section refers to the relevant 
sources describing rationale and structure of our classification. We think this could be sufficient for 
documentation, and would avoid a long additional paragraph in the present article (Page 9) 
  
Centralisation & Expertise 
 
1. I suspect that the figures for mean annual hospital volume are highly skewed (no data shown). This 
calls into question the use of means, rather than medians, in the analysis. This potential objection is 
probably answered by their use of regionally-based mean admission volume as the metric of interest. 
The mean admission volume is effectively a weighted average, and this approach should compensate 
for any difficulties imposed by unequal distributions of activity at the level of the individual centres. 
Perhaps this advantage of their approach needs to be made more explicit. 
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Replay. The reviewer is right: the volume distribution among hospitals is highly left-skewed because 
many hospitals have low volume and very few have high volumes. When considered among patients, 
the volume distribution is much less skewed because many patients are treated in those few high 
volume hospitals.  According to our definition, MAV can be also interpreted as the mean of hospital 
specific volumes  weighted by the number of patients treated. As a consequence, the median 
admission volume over all patients for a given cancer/country combination is not too different from the 
orresponding mean admission volume (MAV) mostly ranging within 0.7-1.2. Correlation between mean 
and median admission volumes over all the entities is between 0.97 and 0.99 for all countries, so they 
basically provide the same information. We added a sentence at the last paragraph of the Methods 
section, Page 10. 
 
2. The mean admission volume estimates will, to a considerable extent, depend upon how specialist 
cancer services are organised. If a biopsy is performed at one hospital, then the patient is referred to 
another hospital for specialist surgery, and then to a third hospital for radiotherapy and chemotherapy, 
then the activity per hospital will be low. If, however, the separate hospitals are grouped 
administratively as a single cancer centre or network then the unit activity will be correspondingly 
higher. The authors' approach is, therefore, sensitive to the way in which cancer services are 
organised, perhaps this is something that ought to be more fully acknowledged as a potential limitation 
to their approach. 
Reply. We accept the comment and modified accordingly a paragraph of the discussion at page 16 
3. The approach used in their analysis would not identify patients being treated across various centres 
using common protocols. You cannot assume therefore that there is a direct correlation between 
access to optimal treatment and number of treatments per centre per year.  
Reply: we partly agree with, registries are not able to reach the information whether a patient is or not 
treated according to an agreed protocol, mainly because this information is rarely reported in the clinical 
record. What we would like to stress is that a high number of diagnosed and treated patients, can 
provide a sound expertise and help to a better application of agreed protocols. This is mainly true for 
complex surgery, but also for high technology radiotherapy or for general management of complex 
patients. However, we are not able to demonstrate that patients with rare cancers are more 
appropriately cured in high volume hospital. Our aim is to address the centralization issues and we 
hope that this is more clear in the reviewed discussion (page 16).  
 
4. Expertise and numerical activity may not be tightly related. The development of the total mesorectal 
excision for rectal cancer, pioneered at Basingstoke, is a good example of how a centre that is small - 
in terms of patients treated per annum - can innovate and generate outcomes that are superior to those 
achieved in busier centres. 
Reply: we recognise the brilliant example of mesorectal excision.  However, this exception  may be 
more applicable to a common cancer, like rectal cancer, for which a critical number of surgically treated 
cases can be reached by a small center.  
 
5. The attractant properties of specific technologies lead to increased localisation of services. It is 
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therefore not surprising that thyroid cancer and sarcomas have higher mean admission volumes than 
would be expected from their incidence, as emerges from the rankings in table S1. The management of 
thyroid cancer requires specialist nuclear medicine facilities and the management of sarcoma is 
critically dependent upon advanced techniques both in surgery and in rehabilitation. 
Reply: We agree that for STS and thyroid specific technologies should lead to increased localisation of 
services. Actually, we observed higher MAV than expected for thyroid and for bone, but not for soft 
tissues sarcomas.(page 13). 
  
6. A recent paper from Korea (Shin DW, Cho J, Yang HK, Kim SY, Lee SH, Suh B, et al. Oncologist 
Perspectives on Rare Cancer Care: A Nationwide Survey. Cancer Res Treat. 2015;47(4):591-9) 
outlines oncologists' views of the problems they encounter in the management of rare tumours. It also 
hints at the potential difficulties that might arise when attempts are made to centralise services for 
patients with rare tumours.  
Reply: We  knew the interesting paper  reported by the reviewer; we are aware that centralization is 
sometimes not perceived as a the ideal solution therefore we include this point of view in the discussion 
(page17). We added a new reference.. 
 
Pathology and Registration 
 
7. The analysis relies on the pathology of up to 20 years ago, and may be of questionable relevance to 
future practice, which will be increasingly based on molecular and genomic classification. 
Reply: we included in the Discussion (Page 20) the point raised by the reviewer. 
 
8. The rise in incidence for gastrointestinal stromal tumours is probably an example of ascertainment 
bias. Once you start performing immune staining for mutant c-kit, then the incidence rises. The authors 
need to discuss the molecular and genetic phenotyping of individual tumours and how this will have an 
impact on the estimates of the incidence of rare tumours and how this might cause fragmentation of 
apparently homogeneous categories. The overall effect would be to decrease the number of patients 
per category. 
Reply: we completely agreed with the reviewer with the example of GIST. In this case the ICD-O 
included a new code and GIST started to be identified by cancer registries. Other new codes, because 
of  new tests, mainly for the haematologic group of neoplasms, were included in the ICD-O. In our 
proposed list, the new entities were not recognised as specific rare entities, because they were grouped 
with other rare entities sharing the same therapeutic approach and expertise, see the group of acute 
myeloid leukaemia. The statement included in the discussion (page 20 ) can answer the question 
raised by the reviewer. 
 
9. A flow diagram (or Venn diagram) indicating which registries contributed to which aspects of this 
study would have been very helpful.  
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Reply: We do not think this request add more information that what was reported in the Material and 
Method section.  
 
10. I was unable to obtain access to the cited reference in Tumori (2017) but note that questions have 
been raised concerning the quality of data from registries in Eastern and Southern Europe (Rare 
Cancers Europe Survey 2012. 
Reply: We attach a pdf version of the Tumori paper, for reviewer’s consideration. We do not know the 
Rare Cancer Europe Survey 2012, but we don’t completely agree with this statement. The study, 
published in Tumori, included data also from Sweden, Ireland, Austria, Belgium, Netherlands, Austria, 
Switzerland and France and no major quality differences were found between registries from different 
European regions.   
 
Minor points 
 
11. A brief description of the Ederer-2 method would be helpful (the reference provided is unobtainable) 
Reply: we provide an alternative citation for relative survival estimation 
Ederer F, Axtell LM, Cutler SJ. The relative survival: a statistical methodology. Natl Cancer Inst Monogr 
1961; 6: 101–21. 
 
12. I'm not convinced that Kaposi's sarcoma should be included with the other sarcomas. It is a virally 
related tumour, it responds to highly active retroviral therapy and it is this factor that has probably had 
the main impact on improving survival from Kaposi's sarcoma. 
Reply: We agree. Actually, Kaposi's sarcoma did not contribute to the incidence and survival rates of 
sarcomas,. It is a separate rare entity.  
13. The sentence on page 13 "centralisation of epithelial ovarian cancers was not slow in Bulgaria and 
Slovenia" is a little difficult to understand. Perhaps it could be rewritten as "in Bulgaria and Slovenia the 
management of epithelial ovarian cancers was highly centralised." 
Reply:  Thanks. We have re written the sentence as suggested.  
 
14. On page 14 there is the statement "the drop in incidence for some of the rare cancers was due to 
the still falling prevalence of smoking". The reference given (16) is to smoking prevalence itself rather 
than to the effects of smoking on the incidence of rare cancers. 
Reply:  we provided a more precise reference, WHO, THE EUROPEAN TOBACCO CONTROL REPORT 
2007, http://www.euro.who.int/__data/assets/pdf_file/0005/68117/E89842.pdf 
 
15. I did not have access to the figure captions: the use of a log scale for the X-axis in Figure 3 
deserves specific comment. 
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Reply:  we added a comment at page 12 and of course we will pay attention to correctly include figure 
captions. 
 
16. Reference 27 in the text is reference 25 in the bibliography (there is no reference 27) 
Reply:  We corrected the reference  
 
17. P15 "like for incidence" - sentence needs rewriting 
Reply:  we rewrited the sentence   
Reviewer #3: First rate study. As a consequence I have little of substance to add. My comments are 
below. 
 
1. Table 2. I assume 95% confidence limits. 
 
2. Table 3. Lower and upper what? I assume 5-year survival is a percentage. 
Reply:  Following the standard practice in presenting funnel plot analysis with a large number of 
statistical units, confidence bound correspond to plus or minus three standard deviations from the zero 
change, corresponding to 99.8% confidence limits. We gave more details in titles of both Tables 2 and 
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3. Abstract. If space permits a sentence of what constitutes a rare cancer to be included. 
Reply:  we have included the information requested . 
 
4. Is death all-cause? 
Reply:  yes, relative survival analysis considers death for all causes, corrected by general population 
mortality rates to eliminate expected deaths not due to cancer (details in references 4 and 7).  
 
5. Given the quality of data there's no reason as to why sex-specific incidence (overall, not by country) 
couldn't be provided 
Reply: we accepted the suggestion and a Supplementary Table is attached 
 
6. Provide a STROBE Statement.  
Reply: we do not understand this point 
 
Final review: 
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My overall comment is that the data are per se interesting, but not particularly new and add to a limited 
amount to what we know and what should be done. 
The part about management is purely ecological and any projections about what type/degree etc of 
centralisation of care is needed to achieve results remain speculative. Hospital volume is also a moving 
target and much has happened since 2007. 
Reply: as far as we know, cancer survival and incidence trends are rarely given. Furthermore, we think 
that our contribution answers to the increasing interest of the EC expressed by the Joint action on Rare 
Cancers and the ERN. Therefore, as stated, this ‘old’ picture will help the evaluation of activities on rare 
cancers at European and country level. 
Editorial comments 
 
1. Please confirm that all authors who qualify for authorship for this manuscript (in adherence with 
ICMJE guidelines) are included in the authorship. 
Replay: Confirm 
 
 
2. Please confirm that all individuals who need to be acknowledged in this manuscript are in the 
Acknowledgments section.  
Replay: Confirm 
 
 
3. If your research is funded by a body with an Open Access agreement in place with Elsevier (ie, by 
one of the Research Councils UK, Wellcome Trust, Cancer Research UK, Arthritis Research Council, 
British Heart Foundation, UK Department of Health, UK Chief Scientist Office, Austrian Science Fund, 
or Parkinson's UK), please consider now which licence you would opt for, should the paper be accepted 
for publication. There are two options - gold Open Access and green Open Access. Further details can 
be found at http://www.thelancet.com/lancet-oncology-information-for-authors/open-access. 
Replay: the research was funded only by the EC.  
Manuscript reference number: THELANCETONCOLOGY-D-17-00424 
Title: Burden, time trends and centralized treatment of rare tumors: a European perspective. The RARECAREnet 
Project 
 
Second revision 
 
1. Please check with your co-authors, and confirm, that all names are spelt correctly, and affiliations listed correctly. We 
cannot guarantee that we will be able to correct names and affiliations after publication of your article. 
Reply: done 
 
2. The study title should have a descriptor—ie, randomised trial, case-control study, prospective analysis, population-
based study etc…  
Reply: done 
 
3. Please supply (after author names on the title page) one preferred degree per author and indicate in the authorship if 
any authors are full professors.  
Reply: done 
 
4. Please give full first names for all authors. 
Reply: done 
 
5. Summary: Your abstract should conform to the CONSORT guidelines for abstracts (CONSORT for Abstracts: Lancet 
2008; 371: 281-83), and must include: 
 
a) Background: A sentence indicating the aim of this study. 
b) Methods: A brief summary of the main patient characteristics (ie, main entry criteria) 
c) Interpretation: please do not just restate your findings. What do they mean, clinically? What are their 
implications? 
d) A line at the end of the abstract stating who funded the research.  
 
See recent issues of the journal for examples. At this stage, please do not worry about the word length of the 
abstract - accuracy and completeness here are essential. 
Reply: done 
 
 
6. Please confirm that your study conforms to the STROBE guidelines by completing and returning the checklist. 
 
STROBE - Observational studies — http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(07)61602-
X/fulltext 
 
http://download.thelancet.com/flatcontentassets/authors/tlo-research-checklist.pdf 
 
nfo: http://www.equator-network.org/ 
Reply: done (see pages 7 and 8) 
 
 
7. If you have included such data for a drug(s), please confirm that the dose, route, and frequency of administration 
(and the form: eg, a particular salt) are correct. 
 
8. It is Lancet style to give actual numbers (numerator and denominator) together with percentages—eg, '5 (50%) of 10 
patients in the treatment group received treatment per protocol'. 
 
9. Please do not translate HRs/RRs/ORs into percentages, since this can be misleading. Simply indicate the 
HRs/ORs/RRs and let the reader interpret the data. 
 
10. Lancet style is to provide p values to 2 significant figures, unless p<0.0001 (if this is the case, then please revise to 
the latter). 
 
Reply: from point 7 to 10, not applicable 
*Reply to Reviewers Comments
 
 
11. Lancet style is to have a 'Role of the funding source' at the end of the methods. The following points need to be 
addressed in the "Role of the funding source" statement: 
 
a) The role of the sponsors in the study design. 
b) The role of the sponsors in the collection, analysis, or interpretation of the data. 
c) The role of the sponsors in the writing of the report. 
d) Those who had access to the raw data (by author initials).  
 
If the funding source had no role then this should be stated. Please also add to this section (if true): "The 
corresponding author had full access to all of the data and the final responsibility to submit for publication." 
Reply: done 
 
 
12. Please give the exact patient enrolment dates (if known)—ie, day, month, year.  
Reply: done 
 
13. Results: please explicitly state the number of patients included in analyses, and the number of patients deemed 
ineligible (and reasons why). 
Reply: done 
 
 
14. If you have claimed a first, please reword to: "To our knowledge… this is the first time...", since you can never be 
100% sure. 
Reply: not applicable 
 
15. Please add a declaration of interest statement to the end of your paper, as per Lancet style. These statements 
should exactly match those given on your ICMJE forms. If there are none then please state "The authors declared no 
conflicts of interest" or "The other authors declared no conflicts of interest." 
Reply: done 
 
 
16. Please add an Author contributions section to the end of your paper before the references, as per Lancet style. 
These statements should exactly match those given on your signed author contribution forms. Authors should be 
referred to by their initials in this section. 
Reply: done 
 
 
17. We require written and signed consent from any individuals who are cited in the acknowledgments section or as 
personal communications. The following format can be used and a signed statement uploaded on resubmission: 
 
* "I permit <corresponding author> et al to list my name in the acknowledgments section of their manuscript and I 
have seen a copy of the paper <full article title>." 
 
* "I permit <corresponding author> et al to cite a personal communication from me in their manuscript <full article 
title>." 
Reply: done 
 
 
18. If a medical writer or editor was involved in the creation of your manuscript, we need a signed statement from the 
corresponding author to include their name and information about funding of this person. 
Reply: not applicable 
 
 
19. References should be in Vancouver style. For references with six authors or fewer, all authors should be listed. For 
those with seven or more authors, then just the first three authors and 'et al' should be listed. Please ensure that 
reference numbering throughout the manuscript is not inserted with electronic referencing software, such as 
Endnote. 
Reply: done 
 
 
20. All web references should have the date they were last accessed. 
Reply: done 
 
 
21. All abstracts and references in press should be updated with DOIs or page numbers as appropriate. For papers 
listed in references that are "in press" we need to see a galley proof and/or letter from the publisher stating that it is 
"in press" as well as (where known) the full expected citation (ie, publication date/volume/issue etc). References that 
are "submitted" should be removed and citations in the text replaced with "(unpublished data; authors)". 
Reply: not applicable 
 
 
22. Please supply figures as high-resolution EPS format, exported directly from your statistical package if possible, 
rather than embedded in a Word file. For more information, see 
download.thelancet.com/flatcontentassets/authors/artwork-guidelines.pdf 
Reply: done 
 
 
23. It is no longer TLO policy to include investigator lists in the main paper; instead, these will be published in the online 
appendix that is linked to the paper; investigators will still be indexed in PubMed.  
Reply: ok 
 
 
24. Please state whether this study was fully or in part NIH funded.  
Reply: no funding from NIH 
 
25. We cannot cite items in the appendix (eg, "see table x in appendix"). Please paginate your appendix, and cite page 
numbers in the main paper (eg, "see appendix p10"). 
Reply: done  
 
 
26. It is no longer Lancet policy to edit or style supplementary material for the web; however, this material will still be 
hosted on our website as a pdf of the author supplied file. Please style your supplementary material as per the 
guidelines below. Please note that we will be unable to correct any errors in the webappendix following publication; 
as such, please check carefully when submitting.  
 
Please supply the webappendix as a single PDF file, with the pages paginated - when you refer to an item in the 
appendix, please refer to the page number on which it appears, not the table or section.  
Reply: done  
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* Exact p values should be provided, unless p<0·0001 
Drug names 
* Recommended international nomenclature (rINN) is required  
References 
* Vancouver style (eg, Smith A, Jones, B, Clements S. Clinical transplantation of tissue-engineered airway. Lancet 
2008; 372: 1201-09. Hourigan P. Ankle injuries. In: Sports medicine. Chan D, ed. London: Elsevier, 2008: 230-47.) 
* Numbered in order of mention in Web Appendix and numbered separately from references in the full paper 
Figures 
* All images must have a minimum resolution of 300 dpi at a width of 107 mm 
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* Legends should be in 10 point, single spaced 
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